American Society of Clinical Oncology Annual Meeting

June 1-5, 2018 Chicago, IL UCSF Presentation Brochure

UCSF HELEN DILLER FAMILY UCSF HELEN DILLER FAMILY CANCER CENTERCOMPREHENSIVE 1 2 EXCEPTIONAL PEOPLE EXTRAORDINARY SCIENCE

For the past three years, it has been my privilege to work with UCSF’s team of exceptional cancer scientists who are helping to transform cancer into a manageable disease, and hopefully one day, a curable disease. Among our many programs, UCSF faculty are driving efforts to overcome drug resistance, a key limitation of targeted therapy; developing drugs against previously undruggable proteins; and making significant advances in cryo-electron microscopy that is allowing scientists to visualize a broad spectrum of proteins at resolutions approaching crystal structure resolutions. We are leading the way on the next generation of cellular therapies, with novel approaches to addressing specificity and efficacy, while minimizing side effects. Also, we’ve expanded our state-of-the-art cancer imaging program to more rapidly assess disease progression and treatment response, creating time to move patients to other therapies when first-line therapies fail.

All of us are working in an exciting new era of collaboration. We recognize that bringing advancements to patients is best accomplished by working in partnership with the broader life science industry. As an NCI-designated comprehensive cancer center, UCSF is recognized for our outstanding science, extensive resources, depth and breadth of our research in basic, clinical, and Alan Ashworth, PhD, FRS population sciences, as well as cutting edge research that bridges these scientific areas. UCSF is home to many of the world’s finest President, oncology clinicians and scientists who understand the power of UCSF Helen Diller Family Comprehensive partnerships. This searchable abstract book of UCSF research Cancer Center presented at ASCO is a resource for potential partners interested in identifying world-class faculty engaged in basic science and clinical Senior Vice President oncology research. for Cancer Services, UCSF Health I invite you to learn more about our work and expertise by reaching out to our faculty during this meeting. If you have additional Professor of Medicine, questions or would like assistance with your outreach, please Division of contact the Director of Strategic Alliances for the Cancer Center: Hematology/Oncology, Cammie Edwards ( ). Department of Medicine I wish you a very productive meeting, and we look forward to future discussions and collaborations.

Alan Ashworth, PhD, FRS

1 OUR SUCCESS IS DRIVEN BY OUR FACULTY HDFCCC Membership: 453 Members & Affiliate Members

2 Nobel Laureates 3 Albert Lasker Award winners 8 Howard Hughes Medical Investigators 16 Members of the National Academy of Sciences 20 Members of the Institute of Medicine 23 Fellows of the American Academy of Arts and Sciences 6 Fellows of the Royal Society

2 UCSF IN THE NEWS (Click on link to read story)

Computers Equal Radiologists in Assessing Breast Density and Associated Breast Cancer Risk http://cancer.ucsf.edu/news/2018/04/30/computers-equal-radiologists-in-assessing-breast-density-and-associated-breast-cancer-risk.8909

Research Finds ‘Achilles Heel’ for Aggressive Prostate Cancer: Treatment-Resistant Cancers Self-Destruct When Exposed to Experimental Drug http://cancer.ucsf.edu/news/2018/05/02/research-finds-achilles-heel-for-aggressive-prostate-cancer.8911

Rising Stars: New Faculty Members Lead to New Discoveries at UCSF http://cancer.ucsf.edu/news/2018/04/17/rising-stars-new-faculty-members-lead-to-new-discoveries-at-ucsf.8893

Gilead Sciences and Kite to Acquire Cell Design Labs, One of UCSF Startups for up to $567MM https://ita.ucsf.edu/news-and-events/gilead-sciences-and-kite-acquire-cell-design-labs-one-ucsf-startups-567-mm

UCSF Welcomes First Vice President/Chief Medical Officer for Cancer Services http://cancer.ucsf.edu/news/2018/05/16/ucsf-welcomes-first-vice-presidentchief-medical-officer-for-cancer-services.8926

New Approach Attacks ‘Undruggable’ Cancers from the Outside In: Antibodies Target Cell Surface Proteins Produced by Ras Mutations http://cancer.ucsf.edu/news/2018/01/23/new-approach-attacks-undruggable-cancers-from-the-outside-in.8739%20%0D

Jason Cyster Elected to American Academy of Arts and Sciences http://cancer.ucsf.edu/news/2018/04/17/jason-cyster-elected-to-american-academy-of-arts-and-sciences.8896

Gene Mapping Lays Groundwork for Precision Chemotherapy http://cancer.ucsf.edu/news/2018/04/17/gene-mapping-lays-groundwork-for-precision-chemotherapy.8894

Cancer-Killing Virus Acts by Alerting Immune System: Vaccine-like Effect Suggests Potential for Combination With Cancer Immunotherapy http://cancer.ucsf.edu/news/2018/02/13/cancer-killing-virus-acts-by-alerting-immune-system.8804

Findings Flip Scientists’ Understanding of Key Growth Switch Involved in Cancer http://cancer.ucsf.edu/news/2018/04/11/findings-flip-scientists-understanding-of-key-growth-switch-involved-in-cancer.8890

UCSF Names First-Ever Chief Genomics Officer http://cancer.ucsf.edu/news/2018/04/12/ucsf-names-first-ever-chief-genomics-officer.8891

3 ADVANCING THE NEXT WAVE OF CANCER TREATMENT BREAKTHROUGHS

Whether it is pioneering novel clinical trial designs; discovering, developing, and bringing to the clinic revolutionary treatments such as immunotherapies; or harnessing the power of big data to drive faster, personalized, and more effective cures, UCSF leads in advancing the next wave of cancer treatment breakthroughs. With a culture of collaboration, a commitment to excellence, and access to cutting-edge laboratory and clinical technologies, UCSF faculty work tirelessly to improve clinical outcomes for cancer patients everywhere.

WORKING TOGETHER ADVANCING THE UNDERSTANDING AND TREATMENT OF CANCER

NCI - Supported Research Programs (click on link to get more information)

• Breast Oncology • Hematopoietic Malignancies • Cancer Control • Neurologic Oncology • Cancer Genetics • Pediatric Malignancies • Cancer Immunology • Prostate Cancer • Experimental Therapeutics • Tobacco Control

Additional Cancer Research (click on link to get more information)

• Cancer Risk • Multiple Myeloma • Gastrointestinal Oncology • Pancreas Cancer • Gynecologic Oncology • Pediatric Brain Tumor Research • Melanoma • Thoracic Oncology

Key Initiatives (click on link to get more information)

• Cancer Immunotherapy • Precision Cancer Medicine Building • Center for BRCA Research • The San Francisco Cancer Initiative (SF CAN) • Global Cancer • UC Cancer Centers Consortium • Molecular Oncology

4 CORE CAPABILITIES SUPPORTING OUR PROGRAMS (click on link to get more information)

Biorepository and Tissue Biomarker Technology Provides optimal acquisition, processing, and storage of human tissue biospecimens, as well as state-of-the-art biomarker histologic detection and/or image analyses for both human and mouse tissue biospecimens.

Biostatistics Provides statistical expertise and collaboration to the UCSF cancer research community on all phases of basic science, translational, clinical, epidemiological, and prevention research.

Cancer Imaging Research Provides technical capabilities and scientific expertise for integrating cutting-edge, multi-modality imaging into basic, translational, and clinical research.

Computational Biology and Informatics Provides computational biology and computational infrastructure support to the UCSF cancer research community.

Laboratory for Cell Analysis Provides cytometric, microscopic, and genomic support and services for the UCSF cancer research community.

Preclinical Therapeutics Offers a complete set of preclinical services and in vivo imaging devices for cancer investigators.

Small Molecule Discovery Collaborates with academics, government labs, and pharmaceutical companies to develop unique chemical probes and drug leads that address unmet medical needs in cancer.

Tobacco Biomarkers Serves as an analytical chemistry resource for the UCSF tobacco control and cancer research community.

5 PRESENTATIONS *UCSF authors in bold

FRIDAY | JUNE 1, 2018

Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma

Authors*: Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Timothy Francis Cloughesy, Howard A. Burris, Elizabeth A. Maher, Filip Janku, Gregory Michael Cote, Macarena Ines De La Fuente, Jennifer Clarke, Lori Steelman, Kha Le, Yanwei Zhang, Alison Sonderfan, Diana Hummel, Steven Schoenfeld, Katharine Yen, Shuchi Sumant Pandya, Patrick Y. Wen

Abstract #: 2002 Abstract link: http://abstracts.asco.org/214/AbstView_214_213689.html Presentation Date/Time: Friday June 1, 2:45 PM to 5:45 PM Location: S102 Presentation Type: Oral Abstract Session Citation: J Clin Oncol 36, 2018 (suppl; abstr 2002)

Clarke Research Interests: Dr. Clarke’s research interest is focused on the development of novel therapeutic strategies for adult patients with primary brain tumors. As a member of the Brain Tumor Center, she is principal and co-investigator on single-institution clinical trials designed and conducted at UCSF, as well as multi-institutional trials, including those supported by the National Cancer Institute’s Adult Brain Tumor Consortium. In addition to clinical trials, her research interests include evaluation of molecular methods of characterizing tumors to individualize treatment, profiling of the immune system to determine the prognostic and predictive value, and novel imaging methods that may more accurately assess tumor biology and response to treatment. In particular, she is interested in finding noninvasive biomarkers that may distinguish treatment effect from recurrent tumor. http://cancer.ucsf.edu/people/profiles/clarke_jennifer.3325

______

Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.

Authors*: David A. Reardon, Lakshmi Nayak, Katherine B. Peters, Jennifer Leigh Clarke, Justin T Jordan, John Frederick De Groot, Phioanh Leia Nghiemphu, Thomas Joseph Kaley, Howard Colman, Sarah C. Gaffey, Victoria Caruso, Myriam Bednarek Debruyne, Chinmay Bhavsar, Annette M Molinaro, Timothy Smith, Mariano Severgnini, Patrick Y. Wen

Abstract #: 2006 Abstract link: http://abstracts.asco.org/214/AbstView_214_221015.html Presentation Date/Time: Friday June 1, 2:45 PM to 5:45 PM Location: S102 Presentation Type: Oral Abstract Session Citation: J Clin Oncol 36, 2018 (suppl; abstr 2006)

6 *UCSF authors in bold ______http://cancer.ucsf.edu/people/profiles/jordan_richard.3466 development the and of more reproducible p16results for HPV methodto report positive cancer. HN research specific interest tissues. rolefrom His studying the includes the embedded of HPV paraffin cancer HN 16 in sourced DNA material RNA in and to aberrations methods quantify cited nowwidely the collaborators established cancers.of oral other cancer, and of these to studies epidemiological and diseases He gland salivary and lymphoma to range awide investigation of scientific development the from examining biologically based, studies mechanistic groups patients enrolling into late stage phase2/phase3cancer trials. Dr. clinical contributed and Jordanled has co-operative funded of 5NCI the largest the Columbus. cancer in is Nationwide Hospital It Children’s the and Pittsburgh tumors. locations Director Francisco, the biobanking San is in He with Banks ofNRG Oncology the Biospecimen Houston, Jordan Research Interests: Dr. neck(HN)/oral ofand head diagnosis the in expertise with apathologist Jordan is Citation: Presentation Type: Location: S100bc Presentation Date/Time: FridayJune 1, to 4:30PM 6:00PM Abstract http://abstracts.asco.org/214/AbstView_214_217507.html link: Abstract #:6010 F. John Blakaj, Deeken,Dukagjin Machtay, Mitchell Walter Curran, John Quynh-Thu Le Richard Jordan, Authors*: carcinoma RTOG cell (HNSCC): neck squamous 3504 local-regionally (HR) advanced and head high-risk and for (IR) intermediate Safety evaluation (Nivo) concomitant cetuximab-radiotherapy of nivolumab with J Clin OncolJ Clin 36, 6010) 2018(suppl; abstr Robert L. Ferris,MauraL.Robert Gillison, Colevas, Harris, A. Jonathan Dimitrios Loren K. Kong, Mell, Christina Kevin Moore, Minh Tam Truong, Kirsch, Claudia David Anthony Clump, Ohr, James He, Kai Clinical Science Symposium 7 *UCSF authors in bold in authors *UCSF

FRIDAY | JUNE 1, 2018 http://profiles.ucsf.edu/laura.esserman cancer screening in 100,000 to and predict women gets who whatof kind cancer. tools. breast &web-based testing the launched vsannual molecular just studyWISDOM to compareAthena personalized to from follow women Network screening through treatment BreastHealth &outcomes,Athena incorporating latest in the I-SPYthe program,TRIAL research for design. nowamodel translational &innovation trial clinical the in Shelaunched to of list. PI Sheis people &wasnamed TIME’s 100 most influential Management in for Excellence School of Business received Investigator SPORE NCI the of the Year Award. received 2016she In the Arbuckle Award from Stanford Graduate through science, integrating translational informatics, care clinical &clinical delivery. re-engineering systems 2005, In she Breast Care Director Center Breast Oncology the co-leads and Program. research Her onimproving is value healthcare Research Interests: Dr.Esserman &breast surgeon cancer Esserman, oncology Carol the specialist, is Franc Buck Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #:520 Smita Asare, MinettaC. Liu, DeMichele,Angela Douglas Yee, Donald A. Berry, Laura Esserman Duan,Xiuzhen Chen, Beiyun Ronald Sattar,Tickman, Husain Magliocco, Anthony Martin Kallakury, Bhaskar Megan Troxell, Authors*: cancerResidual burden (RCB) prognostic as I-SPY the in 2 TRIAL ______http://cancer.ucsf.edu/people/profiles/huang_chiungyu.8706 of virus. founder number the incorporating about information developed statistical has forshe methods efficient evaluating active vaccine with efficacy by trials clinical in surveillance to goal improve data,the with of survival effect prediction analysis the risk in information cancer in patients. Recently, events orcovariate of interest. subgroup survival procedures developed estimation Shealso efficient to auxiliary combine event, informativeunder terminal censoring, where adependent suchdeath, as occurrence precludes further of recurrent recurrent approachesdeveloped novel semiparametric event and for nonparametric analyzing count data datapanel and events, particular, of trials. In clinical data, measurements, monitoring and competing risks, missing longitudinal has she to outcomes, biomedical sciences. the of survival statistical the in recurrent extensive analysis Shehas experience Research Interests:Huang Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract http://abstracts.asco.org/214/AbstView_214_209169.html link: Abstract #:511 L.Richard Wahl, VeredStearns Vicente Valero, Christos Vaklavas, Camp, Melissa Robert S. Miller, AntonioVandana C. Gupta Abramson, A. Lisa Carey,Wolff, Minetta C.Ashley Cimino-Mathews, Liu, F. Mothaffar Rimawi, M. Jennifer Specht, Storniolo, Maria Anna Authors*: breast HER2-positive cancer operable primary patients in with trastuzumab and complete to (pCR) pertuzumab response pathological with tomographyuptake onpositron (SUV) emission (PET) value TBCR SATURDAY ______C026: Phase II clinical trial assessing the correlation the of standardized assessing trial IIclinical C026: Phase J Clin OncolJ Clin 36, 520) 2018(suppl; abstr OncolJ Clin 36, 511) 2018(suppl; abstr Roisin M.Roisin Connolly, Jeffrey P. Leal, Chiung-Yu Solnes, Lilja Carpenter, Huang, Ashley Gaffney, Katy William Fraser Symmans, Christina Yau, Yunn-Yi Chen, http://abstracts.asco.org/214/AbstView_214_231431.html Poster Session Poster Session |

Dr. research Huang’s biostatistics interest general in application methodologyits is and JUNE 2, 2018 2, JUNE 8 Brian Datnow, Brian Shi Wei, DFeldman, Michael JonRitter, *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 https://radonc.ucsf.edu/felix-feng progression, drive disease biomarkers 3)to and develop approaches therapeutic drivers. to target disease these of aggressivenovel biomarkers prostate molecular cancer, by several which mechanisms of the these 2)to understand from abiological perspective, dedicated and goals: laboratory research major his three are team 1) to pursuing identify of treatment resistance developing and strategies to overcome resistance. this To enhance current approaches clinical Dr.Feng’s research program to therapy is individualize aggressive for patients with disease, determinants by identifying Feng Research Interests: Dr. research translational prostate in aleader Fengis Felix cancer. of aim primary The Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #:535 Corey Wayne Speers, Lori J. Pierce, Per Fernö, Malmström, Per Mårten Karlsson http://profiles.ucsf.edu/laura.esserman cancer screening in 100,000 to and predict women gets who whatof kind cancer. tools. breast &web-based testing the launched vsannual molecular just studyWISDOM to compareAthena personalized to from follow women Network screening through treatment BreastHealth &outcomes,Athena incorporating latest in the I-SPYthe program,TRIAL research for design. nowamodel translational &innovation trial clinical the in Shelaunched to of list. PI Sheis people &wasnamed TIME’s 100 most influential Management in for Excellence School of Business received Investigator SPORE NCI the of the Year Award. received 2016she In the Arbuckle Award from Stanford Graduate through science, integrating translational informatics, care clinical &clinical delivery. re-engineering systems 2005, In she Breast Care Director Center BreastOncology the co-leads and Program. research Her onimproving is value healthcare Research Interests: Dr.Esserman &breast surgeon cancer Esserman, oncology Carol the specialist, is Franc Buck Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #:541 Tommy Fornander, Stål, Czene, Olle Kamila Laura Esserman Lindström, Linda NancyAuthors*: Yu, Iftimi,Yau,Adina Christina Laura van ‘t Veer, Nordenskjöld, Bo Benz, Christopher Bbreast cancer:Luminal Retrospective ofSTO-3 the analysis trial Long-term from benefit tamoxifen therapy Luminal for patientsA with and ______Authors*: may bespared adjuvant systemic therapy Comprehensive breast transcriptomic cancer profiling to identify patients that ______J Clin OncolJ Clin 36, 535) 2018(suppl; abstr J Clin OncolJ Clin 36, 541) 2018(suppl; abstr Martin Sjostrom,Martin S. Laura Holmberg, Chang, Davicioni, NickFishbane, YFeng, Felix Erik Elai Hartman, Linda http://abstracts.asco.org/214/AbstView_214_217435.html http://abstracts.asco.org/214/AbstView_214_222977.html Poster Session Poster Session 9 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agents committee Breast Cancer oftranslational Research the of the member meeting, afounding amember Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of 2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: S.Hope Rugo M.Rachel Layman, JaniceM. Lu, Kern, Kenneth Perea,Alan J. Rachelle Kristen Pierce, Brett Houk, Pathan, Nuzhat Authors*: breast cancer (B2151009) (MBC) estrogen receptor with women in therapy positive (ET) (+)metastatic (ER) endocrine and palbociclib with combination study in of Ib gedatolisib Phase ______http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding a member Alliance &is is Committee novelto the to expand patients. available therapies director Shewas the of2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: C. Nicholas Turner, Giorgetti,Carla Gauthier, Roland Eric Yuan Liu, (Ray)Lu, J. Dongrui Dennis Bartlett, Huang Slamon, Cynthia RichardAuthors*: S. Ettl, Cristofanilli, Johannes Finn, Karen Massimo A. Gelmon, Shailendra Verma, Marco Colleoni, ofA PALOMA2 subtype: joint analysis intrinsic and PALOMA3 and Treatment effect of (PAL) palbociclib by prognostic therapy endocrine (ET) plus ______J Clin OncolJ Clin 36, 2018(suppl; abstr 1040) OncolJ Clin 36, 2018(suppl; abstr 1023) Andres Forero-Torres, Dees, Han, Claire Heather Wesolowski, Robert Elizabeth Bardia, PeterAditya Kabos, 1040 1023 http://abstracts.asco.org/214/AbstView_214_212831.html http://abstracts.asco.org/214/AbstView_214_227401.html Poster Session Poster Session Hope S.Hope Rugo 10 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agents committee Breast Cancer oftranslational Research the of the member meeting, afounding amember Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing no oncombining Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Patrick Schnell, (Ray)Lu, Dongrui Bananis, Eustratios Ettl, S. Cristofanilli, Hope Johannes Massimo Rugo, Richard S. Finn Authors*: from randomized 3studies analysis phase 2 and factor receptor 2-negative advanced (HER2–) breast cancer Pooled (ABC): receptor-positivepatients (pts) hormone with growth epidermal (HR+)/human H ______http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding amember Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Authors*: breast cancer administered abemaciclib plus pembrolizumab efficacy,Updated safety, HR+, statusmetastatic of &PD-L1 patients with HER2- ______ematologic adverse events (PAL) palbociclib following dose reduction in J Clin OncolJ Clin 36, 2018(suppl; abstr 1060) OncolJ Clin 36, 2018(suppl; abstr 1059) Sara M.Sara Tolaney, Peter Kabos, MauraN. Dickler, Luca Gianni, Valerie Jansen, Lu,Yi Suzanne Young, S. Hope Rugo Sunil V 1060 1059 http://abstracts.asco.org/214/AbstView_214_228451.html http://abstracts.asco.org/214/AbstView_214_213571.html erma, Seock-Aherma, Im, Ro, Jungsil Marco Bondarenko, Masuda, Colleoni, Igor Shailendra Verma, Norikazu Poster Session Poster Session vel targeted to therapeutics improve &late stagebreast treatmentcancer the early of both (BC). 12 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agents committee Breast Cancer oftranslational Research the of the member meeting, afounding amember Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of 2016 the ASCO Breast Cancer Education Breast Cancer Program. Dr. order in academic large medical centers collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Tudor, Markova, Cristina Denka Iulia Lorraine Joanne Blum, L. Keating Litton Alison Hannah, Jennifer Lee,Kyung-Hun Louis Fehrenbacher, Rinat Yerushalmi, Roche, Hubert Lida Henri Martin, A.Young-Hyuck Miguel Mina, Im, Authors*: (TALA) negative triple and breast(HR+) cancer treated talazoparib with (TNBC) receptor-positive BRCA1/2 hormone mutated (gBRCAmut) of germline Analysis ______http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding a member Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of2016 the ASCO Breast Cancer Education Breast Cancer Program. Dr. order in academic large medical centers collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of BreastOncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Tudor, Cristina Iulia LorraineWolfgang Joanne Eiermann, Blum, L. Keating Litton Alison Hannah, Jennifer Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martin, Roche, Hubert Henri Young-Hyuck S. Hope Authors*: Rugo, Ettl, Johannes E. Natasha Im, Woodward, Denka Markova, Sara A.Anthony Goncalves, Hurvitz, Lee, Kyung-Hun BRCAmutation agermline and physician’s choice of therapy (PCT) advanced patients in with breast cancer (TALA), (PARP) polymerase talazoparib oral an poly ribose inhibitor,ADP to relevant outcomes clinically Efficacy in EMBRACA: subgroups comparing ______J Clin OncolJ Clin 36, 2018(suppl; abstr 1070) OncolJ Clin 36, 2018(suppl; abstr 1069) Hope S.Wolfgang Hope Eiermann, Rugo, Diab, Sami Ettl, Johannes Sara A.Anthony Goncalves, Hurvitz, 1070 1069 http://abstracts.asco.org/214/AbstView_214_218477.html http://abstracts.asco.org/214/AbstView_214_218377.html Poster Session Poster Session 13 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/friedlander_terence.4963 work. to patients us recruit for muchofbiomarker allows our which investigator principal as serve advanced or co-investigator in prostate of trials clinical cancer, onanumber bladder and circulating cells, how to tumor better understand to select help patients for therapy. academic aclinical As oncologist I approaches, cancer, bladder in immunotherapeutic particularly developing in as well as novel biomarkers, such as developing in and novelmalignancies ways therapeutic to treat disease. Ihave aresearch focus developing in novel tract, prostate and bladder specifically cancers. Myresearch basicbiologyof the these focused is onunderstanding cancers in ofgenitourinary the oncologist specializing translational Research Interests: and aclinical Iam Friedlander Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #:4532 Angra,Natasha Abdullah, Essa Shaad Zhang,Jingsong S. Michael Gordon, Degboe,Arnold Gupta, Kumar PralayAshok Mukhopadhyay, Wenmei Huang, Authors*: study 1108 orabove) (second-line phase in treated durvalumab 1/2 dose-escalation with outcomes carcinomaPatient-reported urothelial (PROs) (UC) patients in with ______http://hemonc.ucsf.edu/fonglab/ efficacy. clinical of patients are that and currently are these responses in modulated developingthat may bepredictivespecific biomarkers from maydiffer responders clinical non-responders. clinical We approaches are applying unbiased to studyingantigen- effectors canimmune therapies recruit cancer howspecific in determine patients. Moreover, we have how studied bothimmunity systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we cancer and We vaccines inhibitors investigate checkpoint can enhance suchimmune anti-tumor as howimmunotherapies focus of malignancies. solid immunotherapy in is patients. in and models mouse primary in Our immunotherapies system interactsFong Research focuses Interests: Mylab immune onhowthe tumor cancer exploring as with well as Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #:4521 F.Dean Bajorin Howard Gurney, David I. Quinn, StephaneCuline, Cora N. Nam, Sternberg, Kijoeng Tara L. Frenkl, Rodolfo F. Perini, Nicholas J. Vogelzang, Miguel A. Climent, Daniel Peter Petrylak, Toni K. Choueiri, Andrea Authors*: Necchi, Winald R. Gerritsen, from phase3KEYNOTE-045trial the recurrent, in or vinflunine) advanced follow-up cancer urothelial 2-year (UC): (pembro)Pembrolizumab versus investigator’s choice (paclitaxel, docetaxel, ______J Clin OncolJ Clin 36, 4532) 2018(suppl; abstr OncolJ Clin 36, 4521) 2018(suppl; abstr Peter H. O’Donnell, Hendrik-Tobias S.Arkenau, Srikala Sridhar, Ong, Michael Drakaki,Alexandra I. Alexander Spira, Yves Fradet, De Ronald Bellmunt, Joaquim Wit, David J. Vaughn, Jae-Lyun Lee, Lawrence Fong, http://abstracts.asco.org/214/AbstView_214_210893.html http://abstracts.asco.org/214/AbstView_214_226275.html Poster Session Poster Session Terence W.Friedlander 14 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/matthay_katherine.3386 prognosis and pathways targeting and MYCN kinase for PI3 for and dosimetry treatment. imaging I have involved been pre-clinical uptake, in of targeted combination studies of therapies, MIBG mechanisms MIBG and work,radiotherapy (131I-mIBG). radiopharmaceutical, additionto the In my trial clinical with metaiodobenzylguanidine therapy of development neuroblastoma. the in targeted Ihave and aleader of evaluation response been internationally for targeted for consortium Developmental NANT trials clinical NCI-funded Therapeutics. the lead and Ihave established committee. for UCSF PI Lemonade the Steering the Alex Neuroblastoma Iam onthe of continue Center Excellence and oncology.pediatric Strategy of Neuroblastoma the Group Cancer chair Children’s Iwasthe the in Group for tenyears Program for HDFCCC. the research translational neuroblastoma and and in My research focus trials clinical in is Matthay Research Interests: professor Pediatric Iam the School Malignancies the lead in and of of pediatrics Medicine Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Jeffrey Moscow, K. Matthay, Katherine Sheard, Michael Seeger Robert Richard Sposto, Malvar, Jemily Sun, Jianping C. Kelly Goldsmith, Yael P. Mosse, Granger, Meaghan Seibel, Nita Authors*: refractory/recurrentpatients with neuroblastoma (RR-NB) ch14.18A with phase INANT study of lenalidomide isotretinoin in and (RA) ______http://cancer.ucsf.edu/people/profiles/loh_mignon.3407 children, adolescents, young adults. and generation next for the of national ALL implementing trials and for supervising responsible 2015and in April starting for patients suspected of havingJMML. Dr. Loh Oncology ofChildren’s the currently is Group Chair (COG) ALL committee discoveries,these Dr. testing standard Loh as JMML diagnostictesting, nowutilized CLIA molecular is which established suppressor tumor gene. CBLdiscoveryof and the CBL of and descriptions PTPN11 mutations anewfamilial as From JMML focusedinto trials.in of clinical largely landscape JMML, work has genomic ondissecting the including Their that therapies can and beincorporated into assays (ALL) acute and myelomonocytic leukemia (JMML) lymphoblastic Loh Research Interests: Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Stegmaier,Kimberly Consortium Pediatric LEAP Patrick A. Brown, Gore, Lia Stephen Hunger, Todd Cooper, Michael Lewis B. L. Mignon H. Silverman, Loh, Marian Harris, Gordon Pauly,Melinda Narendra Jeffrey Neerav Shukla, Tyner, Peter D. Cole, Burke, James Michael Gossai, Nathan Authors*: consortium leukemias: A from LEAP report the high-risk Matched targeted relapsed, therapy patients for with pediatric refractory or ______J Clin OncolJ Clin 36, 2018(suppl; abstr 10522) OncolJ Clin 36, 2018(suppl; abstr 10518) Araz Marachelian,Araz Judith Villablanca, Duvalyan,Angela Scarlett G. Czarnecki, Susan Groshen, Denice Tsao-Wei, Yana Pikman, K. Sarah Tasian, Sulis, Luisa Maria Traci M. Blonquist, Kelly W. Maloney, Lynn Jennifer McNeer, 10522 10518 http://abstracts.asco.org/214/AbstView_214_228803.html http://abstracts.asco.org/214/AbstView_214_212975.html Poster Session Poster Session The LohThe focused biochemical has and genomic discoveries juvenile lab ontranslating in 15 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/mueller_sabine.4800 radiation as well agentsas therapy. therapy other combination in agentsand strategies with single agents as nanotechnology, with combination to test new partnerships models. PDX these several in has laboratory The industry directed system (CNS) strategies, central nervous exploring delivery suchconvection as in is (CED) enhanced delivery response. disease circulating with DNA tumor Further, by correlating this and biopsies assessing laboratory the investigates pHGGs. other heterogeneity and genomic of the DIPGs Additionally, of liquid utility the are they exploring (pHGGs). grade particular, gliomas high In pediatric lab other and (DIPG) Mueller the gliomas pontine intrinsic oncology. A key focus development the is characterization and of patient derived xenograft for diffuse models (PDX) Mueller Research Interests: Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Dasgupta,Kohinoor W. Mark Russo, Fox Elizabeth Alberto Broniscer, Darren R Hargrave, Pooja Hingorani, Lindsay Baker Kilburn, Sabine Mueller, Tseng,Lillian Authors*: Nebot, Noelia type progressive1 (NF1) neurofibromas plexiform (PN) orneurofibromatosis tumors relapsed solid adolescentschildren and with dabrafenib in with combination in Phase and alone of trametinib 1 trial ______http://cancer.ucsf.edu/people/profiles/sabnis_amit.7897 Hematology-Oncology. Clinical Phase ofTrials Division Pediatric Hospital Children’s group Benioff Early the ofUCSF the patients within sees UCSF, developed hehas anascentprogram focusing networks. protein addition, ontargets In homeostasis within he mentor, his sarcomas. pediatric with work In fornew therapies high-risk Dr. Trever collaborators Bivona, other and at Research Interests: Dr.Sabnis pre-clinically and validate research to patient-derived identify models uses Sabnis’s Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Fox Elizabeth Amit J. Sabnis, Authors*: children, adolescents, recurrent with young adults and orrefractory tumors solid Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in ______J Clin OncolJ Clin 36, 2018(suppl; abstr 10537) OncolJ Clin 36, 2018(suppl; abstr 10536) Birgit Geoerger,Birgit L. Christopher Moertel, James Whitlock, McCowage, Brian Geoffrey W. Mark Kieran, Ami Vijay Desai, M. Garrett Brodeur, Foster, Jennifer Stacey L. M. Berg, Ellen Basu, Shusterman, Suzanne 10537 10536 http://abstracts.asco.org/214/AbstView_214_214951.html http://abstracts.asco.org/214/AbstView_214_214903.html Margaret Macy, Margaret Poster Session Poster Session of Dr. laboratory The focuses research neuro- ontranslational pediatric in Mueller Sabine Janet Yoon, Karen Gauvain,Karen Maneval,Vanessa Chow Esquibel, Edna Pratik S. Multani, 16 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/matthay_katherine.3386 prognosis and pathways targeting and MYCN kinase for PI3 for and dosimetry treatment. imaging I have involved been pre-clinical uptake, in of targeted combination studies of therapies, MIBG mechanisms MIBG and work,radiotherapy (131I-mIBG). radiopharmaceutical, additionto the In my trial clinical with metaiodobenzylguanidine therapy of development neuroblastoma. the in targeted Ihave and aleader of evaluation response been internationally for targeted for consortium Developmental NANT trials clinical NCI-funded Therapeutics. the lead and Ihave established committee. for UCSF PI Lemonade the Steering the Alex Neuroblastoma Iam onthe ofcontinue Center Excellence and oncology.pediatric Strategy ofNeuroblastoma the GroupCancer chair Children’s Iwasthe the in Group for tenyears Program for HDFCCC. the research translational neuroblastoma and and in Myresearch focus trials clinical in is Matthay Research Interests: professor Pediatric Iam the School Malignancies the lead in and of of pediatrics Medicine Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: K. MatthayKatherine Anasheh Shamirian, Charlotte Hasenauer, Murray Norris, Michelle Haber, Susan G. Groshen, David Simon Ziegler, Authors*: topotecanand for relapsed orrefractory neuroblastoma high-risk NANT 2012-01:Phase cyclophosphamide1 study ofcelecoxib with DFMOand ______http://gustafsonlab.ucsf.edu transcription factor. undruggable an to drug used is inhibitor kinase models, structure-activity and relationships, we have that CD532acts shown whereby a viaanovel mechanism allosteric Aurorainhibit A Kinase downregulates MYCN and protein structures, neuroblastomacells. in co-crystal Using culture cell of conformation-disrupting Aurora compound. lead our A (CD-AURKi)CD532as CD-AURKi with inhibitors These potently considered MYC-protein amodel widely neuroblastoma is driven disease. Mostrecently we have discovered anewclass cancers. adult neuroblastoma and and pediatric of array other a wide high-risk as in well MYCN prominently is amplified MYC driven cancers, neuroblastoma. Pathways regulate which MYC particularly proteins are central to neuroblastoma, as to developthese novel therapies. development discovery and Onefocus the been of has novel targeted to therapies treat Gustafson Research Interests: focuses Gustafson lab onnewbasicbiologicalThe discoveries cancer in leveraging and Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Pei-Chi Kao, Wendy B. London, Steven G. DuBois Jeffrey G. Supko, Andrew E. Place, N. Ezrre, O’Brien, Susan Jane Suzanne Hanna, Chi, Shusterman, Gina Suzanne Authors*: relapsed/refractory tumors, solid tumors, CNS lymphomas and with young children adults and in of CUDC-907 trial Imulticenter Phase ______J Clin OncolJ Clin 36, 2018(suppl; abstr 10558) OncolJ Clin 36, 2018(suppl; abstr 10542) Araz Marachelian,Araz D. Michael Hogarty, Andrea Liu, Flynn, Eugene Kangning W. Gerner, Bruckheimer, Elizabeth TranGustafson,David Stephen Shulman, Carlowicz,Kieuhoa Clay Cecilia Vo, Fox, Elizabeth Jodi Muscal,Ann 10558 10542 http://abstracts.asco.org/214/AbstView_214_230477.html http://abstracts.asco.org/214/AbstView_214_218113.html Poster Session Poster Session 17 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. Breast Forum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding amember Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: D.Mark Pegram, Stew Kroll, Joseph P. O’Connell, Jeffrey L. Vacirca, Thomas Wei, Kevin Tang, Seock-AhAndrew David Im, Seidman S. Hope Rugo, Untch,Michael Denise A. Yardley, Bondarenko, Igor StephenChan, Veronique Dieras, Luca Gianni, Authors*: advanced ormetastatic breast cancer (MBC) receptor HER2-, hormone with patients locally in (Pts) +(HR+) of tesetaxel Contessa: A multinational, multicenter, randomized, phase 3registration study ______http://cancer.ucsf.edu/people/profiles/vo_kieuhoa.7395 tumors. solid with youngchildren adults and towards into trials, working more newclinical incorporationand effective biomarkers of these toxic in therapies less and Vo Research Interests: Myresearch focused career is development onthe of novel prognostic predictive and biomarkers Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Gustafson,Clay Alejandro Sweet-Cordero, K. Matthay, Katherine Steven G. DuBois TranKieuhoa Authors*: Vo, Michlitsch, Gibney Jennifer Avanthi T Shah, Long-Boyle, Janel Kim, Mi-Ok advanced sarcoma with for young children adults and temozolomide (PAZIT) and irinotecan with combination in pharmacokinetics, of pazopanib pharmacodynamics and Phase 1 multicenter trial to tolerated assessthe maximum dose, safety, ______J Clin OncolJ Clin 36, 2018(suppl; abstr TPS1106) OncolJ Clin 36, 2018(suppl; abstr TPS10576) Joyce O’Shaughnessy, J. Lee Martine Piccart-Gebhart, Steven Schwartzberg, Cortes, Harbeck, Javier Nadia TPS1106 TPS10576 http://abstracts.asco.org/214/AbstView_214_219045.html http://abstracts.asco.org/214/AbstView_214_229585.html Poster Session Poster Session 18 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 taxane, and capecitabine (ATC) capecitabine taxane, and previously (BM) metastases brain anthracycline, treated an stable with a patientschoice in (pts) metastatic (TPC) with breast cancer have who (MBC) ATTAIN: vs. (EP) 3study of pegol Phase etirinotecan treatment of physician’s ______http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding a member Alliance &is is Committee novelto the to expand patients. available therapies director Shewas the of2016 the ASCO Breast Cancer Education Breast Cancer Program. Dr. order in academic large medical centers collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Antonia Ridolfi, Chinjune Lin, Eva Ciruelos Borrego, Ruiz I.Manuel Linnea Chap, Brown-Glaberman, Carolyn Ursa Abigail C. Nienstedt, NikosSophos, S. Hope Authors*: Rugo, Giulia Valeria Bianchi, Stephen K. L. C. Chia,Nicholas Turner, Juric, Dejan Jacot,William (CDK4/6i) therapy cancer (aBC)progressing 4/6inhibitor on/after kinase cyclin-dependent factor growth epidermal receptorhuman 2-negative advanced (HER2–) breast for treatment of PIK3CA(LET) mutant, receptor-positive hormone (HR+), BYLieve: fulvestrant or letrozole with (FUL) (ALP) A phaseIIstudy of alpelisib ______Authors*: http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agents committee Breast Cancer oftranslational Research the of the member meeting, afounding amember Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of 2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Twelves,Chris Véronique Diéras, Volkmar Mueller, Ann Tagliaferri, Hannah, Mary Alison Cortés Javier J Clin OncolJ Clin 36, 2018(suppl; abstr TPS1107) J Clin OncolJ Clin 36, 2018(suppl; abstr TPS1111) Debu Tripathy, M. Sara Tolaney, Andrew David Seidman, Carey K. Anders, K. Nuhad Ibrahim, S. Hope Rugo, TPS1107 TPS1111 http://abstracts.asco.org/214/AbstView_214_215419.html http://abstracts.asco.org/214/AbstView_214_218425.html Poster Session Poster Session 19 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://hemonc.ucsf.edu/fonglab/ efficacy. clinical patients are that and currently are these responses in modulated developing that may bepredictive biomarkers of from maydiffer responders non-responders. clinical We approaches are applying unbiased to studying antigen-specific effectors can immune therapies recruit cancer howspecific in determine patients. Moreover, we have howclinical studied bothimmunity systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we cancer and We vaccines inhibitors investigate checkpoint can enhance such immune anti-tumor as howimmunotherapies focus ofmalignancies. solid immunotherapy in is patients. in and models mouse primary in Our immunotherapies system interactsFong Research focuses Interests: Mylab immune onhowthe tumor cancer exploring as with well as Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Cora N. Sternberg, Chen, Mei Lei Pang, Munteanu, Mihaela Yufan Zhao, David C. Smith Authors*: chemotherapy: KEYNOTE-698/ECHO-303 platinum-containing advanced ormetastatic carcinoma urothelial after (UC) of first-line failure (pembro) epacadostatPembrolizumab plus orplacebo for locally ______http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding a member Alliance &is is Committee novelto the to expand patients. available therapies director Shewas the of2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June 8:00 toAM 11:30 AM Abstract link: Abstract #: Storniolo, Maria Anna Brufsky,Adam Vandana Gupta Abramson, S. Hope Rugo Authors*: correlative genomic and immunologic studies breast in cancer disease, alone wall chest carboplatin patients with with death) cell 1 antibody, compared to carboplatin with combination in A randomized phaseIIstudy of pembrolizumab, (programmed anti-PD an ______J Clin OncolJ Clin 36, 2018(suppl; abstr TPS4586) OncolJ Clin 36, 2018(suppl; abstr TPS1113) Thomas Powles, Joaquim Bellmunt, Daniel Peter Petrylak, Lawrence Fong, Hiroyuki Nishiyama, Vidula,Neelima TPS4586 TPS1113 http://abstracts.asco.org/214/AbstView_214_223617.html http://abstracts.asco.org/214/AbstView_214_231171.html Poster Session Poster Session Andrei Goga, Hwang, Jimmy MinettaC. Liu, Pohlmann, HoPark, Raffin Paula Ben Nanda, Rita 20 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/palefsky_joel.3581 including currently active India, CostaRica in and studies Thailand. anoscopy,high-resolution in biopsy, anal treatment. office-based and Ihave active an research program, international Clinic,Neoplasia Education Research and at Center UCSF, from Ioversee of clinicians around world the training prevents lesions intraepithelial cancer HIV-infected anal in women. and men director and founder the As of the Anal squamous treatmenthigh-grade whether to of determine anal designed randomized controlled trial NCI/NIH-funded of HPV-relatedtrials population. this in protocol the Iam disease of the study, chair ANCHOR eight-year, an 15-site biology of HPV infection HIV-positive in of research clinical implementation and design the in and women and men of head the the HPV and AMC Consortium Virology Core Lab. Ihave molecular studyingthe in extensive experience ofHPV the chair Palefsky Researchand Interests:founder the Iam Working Group Malignancy ofNCI the AIDS Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #: Authors*: young men: end-ofstudy analysis 10-year Long-term HPV of quadrivalent effectiveness vaccine immunogenicity and in ______http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 in breast cancer. interested is developing Research in Interests: lab Our Munster novel strategies to overcome therapy hormone resistance Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #: Pagan Morris, Kelly Williams, Pamela N. Munster Sachdev Dhawan, Mallika Authors*: Inokuchi, Budge, Jason Lovick, Niki Kerry Mak, Julie Zhou,Alicia Stedden,Will cancerPopulation and pilot protocol testing health (PHACT) ______J Clin OncolJ Clin 36, 2018(suppl; abstr 1553) OncolJ Clin 36, 2018(suppl; abstr 1546) Stephen Goldstone, Giuliano, Palefsky,Anna Joel Luxembourg, Alain of the onbehalf V501-020 study team 1553 1546 http://abstracts.asco.org/214/AbstView_214_224765.html http://abstracts.asco.org/214/AbstView_214_225451.html Poster Session Poster Session 21 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/clarke_jennifer.3325 treatment effectmay distinguish from recurrent tumor. to response treatment. biology and tumor particular, In assess noninvasive that interested is finding she in biomarkers prognostic system the to determine predictiveimmune and value, novel that and methods may more accurately imaging interests include evaluation of to treatment, methods characterizing tumors individualize of molecular profiling of the Cancer by Brain National the Adult Institute’s Tumorsupported additionto research trials, Consortium. her In clinical conducted and designed at UCSF, trials clinical trials, includingthose on single-institution multi-institutional as well as tumors. brain ofBrain the Tumor amember As primary patientsfor with adult Center, co-investigator and principal is she Research Interests: Dr.Clarke research interest Clarke’s focused is development onthe of novel strategies therapeutic Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:2037 Severgnini,Mariano Patrick Y. Wen, David A. Reardon J.Martin Taphoorn, Victoria Debruyne, Caruso, Bhavsar, Bednarek Myriam Chinmay Annette MMolinaro, FrederickJohn De Groot, Leia Phioanh Nghiemphu, JosephKaley,Thomas Howard Colman, Terri Armstrong, Authors*: recurrentpatients with glioblastoma of antibody, anti-PD1 II trial in bevacizumab orwithout with pembrolizumab neuro-oncology in scale aprospective in (NANO) Neurologic assessment phase ______http://cancer.ucsf.edu/people/profiles/ko_andrew.3444 Pancreatic of NCI’s amember as serve Cancer Task Force Pancreatic NCCN the and committee. Cancer guidelines Oncology Society of Clinical American (ASCO), Oncology, currently of am Clinical an Associate for Journal Editor the and biomarkers. program Ihave scientific onthe served committee, board for grants the committee,editorial specialty and characteristics blood-based therapies, prognosis and that to influence response specific and tissue- includingboth cytotoxics targeted patient/tumor individual agentsto to immunotherapies. molecularly Myinterests include identifying also collaborators developing in from agents ranging of newtherapeutic evaluating and novel avariety industry multiple Institute, acareer development award from Oncology Society the of Clinical American (ASCO), have with and partnered onpancreaticemphasis cancers. gastroesophageal and Ihave received research from Cancer funding National the research and clinical interests focus aparticular malignancies, with ongastrointestinal Ko Research Interests: Myprimary Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #: Eric Andrew Collisson, Andrew H. Ko EvanAuthors*: Justin Walker, Julia C. Carnevale, Christina Pedley, Amie Blanco, Salina Chan, (PC) patients pancreatic in rate testing attrition and Referral patterns for cancer germline ______J Clin OncolJ Clin 36, 2037) 2018(suppl; abstr OncolClin 36, 2018(suppl; abstr 1591) Lakshmi Nayak, Timothy Smith, Sarah C. Gaffey, Katherine B. Peters, Jennifer Leigh Clarke, TJordan, Justin 1591 http://abstracts.asco.org/214/AbstView_214_218843.html http://abstracts.asco.org/214/AbstView_214_215777.html Poster Session Poster Session 22 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 Authors*: trial phase 1-2 Dianhydrogalactitol of a bevacizumab-refractory in analysis Further GBM: ______Authors*: longer-term with response Correlation of immune survival of SL-701 2trial Phase relapsed/refractory in (GBM): (r/r)glioblastoma ______https://www.ucsfhealth.org/nicholas.butowski meetings. presented and international atand papers work national a range of novel biomarkers. of Ihave peer-reviewed authored targets, imaging anumber and also markers molecular initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with trials. investigator surgically Ihave and based designed also trials of immunotherapy tumors, assortment includingan spine and brain primary for patients with research portfolio neuro-oncology in allied trial clinical extensive an and UCSF Brain ofUCSF Tumor the behalf Preclinical and Research Center Core. to create helped has groundwork Mywork the for strategies.combination Director the Iam of Translational on effort Neuro-Oncology Research in translational the lead and imaging, targeted convection-enhanced MRI agents, real-time with those with immunotherapy, (CED) delivery and Research Interests:Butowski My research research range includestranslational awide of trials, and including clinical Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract http://abstracts.asco.org/214/AbstView_214_231567.html link: Abstract #:2061 Howard A.Burris Jones, Fields JeffreySuzanne A. Brown, Bacha, Dennis Richard Sarath Stephen Schwartz, Kanekal, C.I. John Constant, https://www.ucsfhealth.org/nicholas.butowski meetings. presented and international atand papers work national a range of novel biomarkers. of Ihavepeer-reviewed authored targets, imaging anumber and also markers molecular initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with trials. investigator surgically I have and based designed also trials of immunotherapy tumors, assortment includingan spine and brain primary for patients with research portfolio neuro-oncology in allied trial clinical extensive an and UCSF Brain ofUCSF Tumor the behalf Preclinical and Research Center Core. to create helped has groundwork Mywork the for strategies.combination Director the Iam of Translational on effort Neuro-Oncology Research in translational the lead and imaging, targeted convection-enhanced MRI agents, real-time with those with immunotherapy, (CED) delivery and Research Interests:Butowski Myresearch research range includes translational awide of trials, and including clinical Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract http://abstracts.asco.org/214/AbstView_214_229695.html link: Abstract #:2058 Sherman,Jonathan Trishna Goswami, David A. Reardon Ashby,LynnStuart Frank S. Lieberman, Surasak Phuphanich, M. Erin Dunbar, Tobias Walbert, David Schiff, David Dinh Tran, J Clin OncolJ Clin 36, 2061) 2018(suppl; abstr OncolJ Clin 36, 2058) 2018(suppl; abstr Kent C. Shih, Manish R. Patel, A.Butowski, Steven Nicholas Gerald Falchook, Kizilbash, Haider Sani David M. Peereboom, Louis B. Nabors, Priya Kumthekar, Michael A. L. Karen Badruddoja, Fink, Nicholas A.Butowski,Nicholas Poster Session Poster Session Fabio Massaiti Iwamoto,Fabio Massaiti Lindsay, Ross Bullington, John Schulder, Michael 23 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://hemonc.ucsf.edu/fonglab/ efficacy. clinical patients are that and currently arethese in responses modulated developing that maybepredictive biomarkers of from maydiffer responders non-responders. clinical We approaches are applying unbiased to studying antigen-specific effectors can immune therapies recruit cancer howspecific in determine patients. Moreover, we have howclinical studied bothimmunity systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we cancer and We vaccines inhibitors investigate checkpoint can enhance suchimmune anti-tumor as howimmunotherapies focus ofmalignancies. solid immunotherapy in is patients. in and models mouse primary in Our immunotherapies system interactsFong Research focuses Interests: Mylab immune onhowthe tumor cancer exploring as with well as Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5019 Authors*: castration-resistant prostate cancer (mCRPC) KEYNOTE-046: (pembro) metastatic in ADXS-PSA pembrolizumab plus ______https://radonc.ucsf.edu/felix-feng progression,disease 3)to and develop approaches therapeutic drivers. to target disease these of aggressivebiomarkers prostate cancer, by several drive which biomarkers mechanisms of the these 2)to understand perspective, dedicated and goals: laboratory research novel major his three are team 1) to pursuing identify molecular resistance developing and strategies to overcome resistance. this To enhance current approaches clinical from abiological research program to therapy is individualize aggressive for patients of with treatment disease, determinants by identifying Feng Research Interests: Dr. research translational prostate in in aleader Fengis Felix cancer. of Dr. aim primary The Feng’s Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5012 YFeng,Felix Authors*: prediction of mCRPC in therapyVeliparib benefit characterization genomic and Phenotypic of CTCs for abiomarker as ______J Clin OncolJ Clin 36, 5019) 2018(suppl; abstr OncolJ Clin 36, 5012) 2018(suppl; abstr Mark N. Stein, Lawrence Fong, F Ronald Tutrone, Stein, N. Anthony E. Lobo, Mega,Maurice Mark Hong, Quan B. Naomi Haas Ryan Dittamore, Yipeng Wang, Daignault-Newton, Stephanie Walter Stadler, Michael Jendrisak, Adam http://abstracts.asco.org/214/AbstView_214_211451.html http://abstracts.asco.org/214/AbstView_214_227321.html Angel EDago,Angel Lee, Jerry Ryon PGraf, Andrew Mark Landers, Hussain Chinnaiyan, Maha Arul Poster Session Poster Session 24 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/small_eric.3671 resistance orprevented, maybedelayed profoundly improving care the affected of men fatal disease. by this progression. them, disease expectedallowing such is “adaptive”inhibiting it and that treatment Byidentifying mechanisms therapy for prostate cancer processes occurs to evade ultimately cancer therapies, exploitcommoncellular when the cells Research Interests: Dr.Small current research that Small’s resistance program hypothesis Eric the to in hormonal based is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5032 Authors*: nonmetastatic castration-resistant prostate cancer (nmCRPC) overall (MFS) and (OS)in Association of survival metastasis-free survival ______http://cancer.ucsf.edu/people/profiles/small_eric.3671 treatment resistance orprevented, maybedelayed profoundly improving care the affected of men fatal disease. by this progression. them, disease expectedallowing such is “adaptive” inhibiting it and that Byidentifying mechanisms therapy for prostate cancer processes occurs to evade ultimately cancer therapies, exploit commoncellular when the cells Research Interests: Dr.Small current research that Small’s resistance program hypothesis Eric the to in hormonal based is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5027 Dearstyne,Erica Dwayne Campogan, Haynes, Heather Tuyen Vu, Sheikh,Anwar Nadeem Jay Small Eric Authors*: prostate cancer (mCRPC) overall patientsand (OS)in (pts) metastatic with castration survival resistant sipuleucel-T between Relationship (sip-T) cytolytic T lymphocyte(CTL) activity ______J Clin OncolJ Clin 36, 5032) 2018(suppl; abstr OncolJ Clin 36, 5027) 2018(suppl; abstr Charles G.Charles Drake, S. Emmanuel Antonarakis, Daniel Peter Petrylak, David I. Quinn, Adam S. Kibel, Nancy N. Chang, Matthew Raymond Smith, Maneesha Mehra, Sandhya Nair, Smith, Raymond Matthew Maneesha Lawson, Joe Jay Small Eric http://abstracts.asco.org/214/AbstView_214_218475.html http://abstracts.asco.org/214/AbstView_214_214159.html Poster Session Poster Session 25 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/small_eric.3671 treatment resistance orprevented, maybedelayed profoundly improving care the affected of men fatal disease. by this progression. them, disease expectedallowing such is “adaptive”inhibiting it and that Byidentifying mechanisms therapy for prostate cancer processes occurs to evade ultimately cancer therapies, exploit common cellular when the cells Research Interests: Dr.Small current research that Small’s resistance program hypothesis Eric the to in hormonal based is Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5034 Lopez-Gitlitz,Angela Oliver Rooney, Brendan Youyi Shu, Darif, Mohamed Smith Raymond Matthew Jay Small,Fred Eric Authors*: Saad, Dana E. Rathkopf, A. Boris Hadaschik, Chowdhury, Simon Margaret K. Yu, phase 3SPARTAN trial castration-resistant prostate from cancer the (nmCRPC): analysis An Predicting progression disease patients in (pts) nonmetastatic with ______http://cancer.ucsf.edu/people/profiles/small_eric.3671 resistance orprevented, maybedelayed profoundly improving care the affected of men fatal disease. by this progression. them, disease expectedallowing such is “adaptive”inhibiting it and that treatment Byidentifying mechanisms therapy for prostate cancer processes occurs to evade ultimately cancer therapies, exploitcommoncellular when the cells Research Interests:Small Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5033 Lopez-Gitlitz,Angela Oliver Rooney, Brendan Darif, Mohamed Jay Small Eric Authors*: fromResults phase 3SPARTAN the trial (pts) nonmetastatic castration-resistant with prostate cancer (nmCRPC): patients in site of and metastases (TTM) to of metastasis time Relationship ______J Clin OncolJ Clin 36, 5034) 2018(suppl; abstr OncolJ Clin 36, 5033) 2018(suppl; abstr Matthew Raymond Smith, Raymond Matthew Fred Saad, DanaE. Rathkopf, A. Boris Hadaschik, Chowdhury, Simon Margaret K. Yu, http://abstracts.asco.org/214/AbstView_214_218505.html http://abstracts.asco.org/214/AbstView_214_218493.html Poster Session Poster Session Dr. current research that Small’s resistance program hypothesis Eric the to in hormonal based is 26 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/cooperberg_matthew to project.advisor the Urological physicianAssociation senior to as to develop serve &continues national launch the and AUA registry Quality better-informed make men byhelping the efforts treatment led American about optionshas He decisions &management. relativethe of cancer of treatments terms benefits in control, survivorship, and QoL, support &cost;4)decision and prognosticvalidating tests;3)comparative imaging tools including novel and effectiveness biomarker research, examining developing of diagnostic, use the assessment, in & variation & regional 2)risk interventions; &therapeutic imaging research malignancies. His GU focus prostate is cancer, research, in services 1) health documenting particularly trends Research Interests:Cooperberg Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5041 Brown, Bruce J. Andrew Armstrong David F. Penson, Schnadig, Mehlhaff, L. Ian James Bailen, Bryan Nancy N. Chang, Sheikh,Anwar Nadeem Pieczonka, Michael Jeff Christopher Vacirca, SConcepcion, Raoul F Ronald Tutrone, Luke T. Nordquist, Carl A Olsson, Authors*: castration-resistant prostate registry cancer PROCEED (mCRPC): patients in (pts) metastatic with prostate-specific(BL) (PSA)quartiles antigen S ______http://cancer.ucsf.edu/people/profiles/aggarwal_rahul.7339 morewith extensive subtypes. disease, disease biologic differences these ifthere to are between understand intrinsic program provide to characterize will genomically patients compare and with mechanism oligometastatic the disease course. disease their in we anticipate to infrastructure percentage biopsyThe alarger patients begin earlier as of this oligometastatic disease. with those approximately far Thus 10% of patients our have oligometastatic disease, and prostate cancer consortium, characterizing focused metastatic genomically and biopsies, tumor onclinically including cancer. Co-Investigator as Iserve Prostate ongoing the in Cancer Foundation/SU2C-funded West Dream Coast Team program focused developing is upon strategies advanced for novel patients with prostate imaging and therapeutic Oncology Developmental and programs.Therapeutics Genitourinary the Hematology/Oncology Myresearch within of Medicine, Professor Department Clinical Research the Interests: in an of Iam Medicine Assistant Aggarwal Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5039 Denise Playdle, Felix Y. Feng, N. Jay Kim Small Eric Chi, Stuart, Josh J.Joshi Alumkal, Verena Friedl, Alana Weinstein, Evan Reiter, Robert Gleave, Rettig, Matthew Lara, Primo Martin Foye, Adam Authors*: DNA ______Prostate Cancer Dream Team castration resistant prostate cancer Data (mCRPC): from the West Coast prostate of distinct cancer subgroups of hallmarks metastatic (t-SCNC) as ipuleucel-T (sip-T) outcomes overall clinical by (OS)and baseline survival repair mutations and treatment-emergent small cell neuroendocrine Rahul Raj Raj Aggarwal, Paul Lloyd, Rahul Huang, Jiaoti Tomasz M. Beer, V.George Zhang, Li LawrenceD. Thomas, True, J Clin OncolJ Clin 36, 5041) 2018(suppl; abstr OncolJ Clin 36, 5039) 2018(suppl; abstr A. Oliver Sartor, S. Celestia Higano, R. Matthew J. Nicholas Cooperberg, Vogelzang, Shaker R. Dakhil, http://abstracts.asco.org/214/AbstView_214_223343.html http://abstracts.asco.org/214/AbstView_214_222515.html Poster Session Poster Session Dr. detection, interests clinical are Cooperberg’s early of &management diagnosis 27 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://hemonc.ucsf.edu/fonglab/ clinical efficacy. patientsare that and currently are these responses in modulated developingthat maybepredictive biomarkers of from maydiffer responders non-responders. clinical We approaches are applying unbiased to studying antigen-specific effectors can immune therapies recruit cancer howspecific in determine patients. Moreover, we have howclinical studied bothimmunity systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we cancer and We vaccines inhibitors investigate checkpoint can enhance suchimmune anti-tumor as howimmunotherapies focus of malignancies. solid immunotherapy in is patients. in and models mouse primary in Our immunotherapies system interactsFong Research focuses Interests: Mylab immune onhowthe tumor cancer exploring as with well as Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5072 Paciorek, Kandadi, Alan Zhang, Li Authors*: Harini Nancy N. Chang, Sheikh,Anwar Nadeem Lawrence Fong after sipuleucel-Tsurvival (sip-T) treatment for prostate cancer receptor B-cell the in Association of changes overall repertoire with (BCR) ______https://radonc.ucsf.edu/felix-feng progression,disease 3)to and develop approaches therapeutic drivers. to target disease these of aggressivebiomarkers prostate cancer, by several drive which biomarkers mechanisms of the these 2)to understand perspective, dedicated and goals: laboratory research novel major his three are team 1) to pursuing identify molecular resistance developing and strategies to overcome resistance. this To enhance current approaches clinical from abiological research program to therapy is individualize aggressive for patients of with treatment disease, determinants by identifying Feng Research Interests: Dr. research translational prostate in in aleader Fengis Felix cancer. of Dr. aim primary The Feng’s Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:5045 Melanie Hullings, Howard I. Scher,Feng, Y Felix Authors*: Clinical study Trials Consortium castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer CC-115 plus c15-160: (ENZA) metastatic with men in Enzalutamide ______J Clin OncolJ Clin 36, 5072) 2018(suppl; abstr OncolJ Clin 36, 5045) 2018(suppl; abstr Dana E. Rathkopf, Karen A. Autio, S. Emmanuel Antonarakis, Heather H. Cheng, Gabrielle Arauz, Annelise Slack, http://abstracts.asco.org/214/AbstView_214_224959.html http://abstracts.asco.org/214/AbstView_214_225015.html Poster Session Poster Session Karen E. Knudsen 28 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/aggarwal_rahul.7339 more extensive subtypes. with disease, disease biologicdifferences these ifthere to are between understand intrinsic program provide to characterize will genomically patients compare and with mechanism oligometastatic the disease course. disease their in we anticipate to infrastructure percentage biopsyThe alarger patients begin earlier as of this oligometastatic disease. with those approximately far Thus 10% ofpatients our have oligometastatic disease, and prostate cancer consortium, characterizing focused metastatic genomically and biopsies, tumor onclinically including cancer. Co-Investigator as Iserve Prostate ongoing the in Cancer Foundation/SU2C-funded West Dream Coast Team program focused developing is upon strategies advanced for novel patients with prostate imaging and therapeutic Oncology Developmental and programs.Therapeutics Genitourinary the Hematology/Oncology Myresearch within of Medicine, Professor Department Clinical Research the Interests: in an of Iam Medicine Assistant Aggarwal Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #: Eunice Aikins-Afful, J. Parsons, JKellogg Charles Ryan, J. Michael Morris Douglas Weckstein, Mohler, James Watson, Mark Taplin, Mary-Ellen Linda A. Pereji, Skoog-Sluman, Meryl Scott Aggarwal, E.Raj Eggener, Rahul Authors*: C. Ronald Chen, Heller, Glenn Patnaik,Akash Xiao, Han relapsed prostate cancer: (AFT-19) An Alliance Foundation trial biochemically A high-risk phase 3study in of androgen annihilation ______http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 in breast cancer. interested is developing Research in Interests: lab Our Munster novel strategies to overcome therapy hormone resistance Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #:6031 Pamela N. Munster, Tanguy Y. Everett Seiwert, E. Vokes Authors*: carcinoma cell (HNSCC) squamous Alliance A091101 (Carbo-Tax)to induction neck and head carboplatin-paclitaxel patients in with (PARP) polymerase veliparib inhibitor addingpoly(ADP-ribose) A phase I/IItrial ______J Clin OncolJ Clin 36, 2018(suppl; abstr TPS5090) OncolJ Clin 36, 6031) 2018(suppl; abstr Michael J.Michael Jelinek, R. Nathan Foster, J. Alexander Zoroufy, K. Jonas A. Schwartz, De Souza, Gary TPS5090 http://abstracts.asco.org/214/AbstView_214_220041.html http://abstracts.asco.org/214/AbstView_214_221187.html Session: Genitourinary (Prostate) Cancer Genitourinary Session: Poster Session 29 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://profiles.ucsf.edu/gabriel.mannis acutecommonly leukemias, myelodysplastic syndromes myeloproliferative and neoplasms. targeted agents. molecularly and Accordingly, research his includesadiverse of array hematologic malignancies, most for treatment patients viamore strategies, personalized study includingthe of novel approaches immunotherapeutic Research Interests: Dr.Mannis investigator aclinical/translational is to research whose improve Mannis aims outcomes Citation: Presentation Type: Location: E450 Presentation Date/Time: Saturday 2, June to 3:00PM 6:00PM Abstract link: Abstract #: Richard M. Stone, M. Hagop Kantarjian William Bruce Donnellan, Arnaud Pigneux, Amir Tahmasb Fathi, Hua Liu, Bin Wu, Eyal C. Attar,Alice S. Mims, Ronan T. S. Martin Swords, Tallman, JessicaK Collins,Altman, Gabriel N. Robert Mannis, Authors*: of (R/R aphase Results leukemia AML): 1 study (IVO;Ivosidenib AG-120) relapsed/refractory IDH1 mutant in acute myeloid ______http://cancer.ucsf.edu/people/profiles/carroll_peter treatmentthe of prostate cancer. of Defense ProstateDepartment Cancer Research Program Transformative Impact Award revolutionize” to and “transform avoid radical treatment treatment. from from maybenefit who early 2013, those In hewas awarded a$9.35 million-dollar factors lifestyle and novel as markers predictorsimaging patients maysafely progression who of disease to distinguish atenrolled nationwide. 43sites prostate Other cancer research focus efforts onquantitative metabolic, molecular, and refine eligibility, safety, of for over surveillance. monitoring for and PI CaPSURE, is registry He adisease 15,000 men active cancer, lowrisk utilizing with in for men leader surveillance international to studies collaborating numerous in recurrence, of disease determinants progression, improving and diagnostics prognostics. and mortality; and an is He Carroll Research Interests: Citation: Presentation Type: Location: Hall A Presentation Date/Time: Saturday 2, June to1:15 PM 4:45PM Abstract link: Abstract #: Strack,Thomas Vincent A. DiPippo, JessicaDonato Jensen, Mahmood, Syed Vivien Wong, J. Kenneth Pienta Shivaram Ajjai Alva,A. Mark Preston, Patnaik,Akash Michael A. Gorin, Jeremy C. Durack, Nichols, Melissa Tess Lin, Authors*: prostatepatients with of diagnostic accuracy cancer: Examination (OSPREY) A prospective study phase2/3multicenter of 18F-DCFPyL PET/CT in imaging ______J Clin OncolJ Clin 36, 2018(suppl; abstr 7000) OncolJ Clin 36, 2018(suppl; abstr TPS5092)

Peter Carroll, J.Michael Morris,Peter Daniel Daniel DentonAaron Pollyea, Dinardo, Courtney StéphanedeBotton, Stein, Eytan J. Gail Roboz, 7000 TPS5092 http://abstracts.asco.org/214/AbstView_214_217175.html http://abstracts.asco.org/214/AbstView_214_220809.html Oral AbstractSession Poster Session Dr. Carroll’s prostate cancer pathologic research and clinical interests include identifying Stephan Probst, Frederic Pouliot, LawrenceA. Saperstein, Siegel, Barry 30 Geoffrey L. Geoffrey Uy, *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 http://cancer.ucsf.edu/people/profiles/mueller_sabine.4800 radiation as well agentsas therapy. therapy other combination in agentsand strategies with single agents as nanotechnology, with combination to test new partnerships models. PDX these several in has laboratory The industry directed system (CNS) strategies, central nervous exploring delivery such convection as in is (CED) enhanced delivery response. disease circulating with DNA tumor Further, by correlating this and biopsies assessing laboratory the investigates pHGGs. other heterogeneity and genomic of the DIPGs Additionally, of liquid utility the are they exploring (pHGGs). grade particular, gliomas high In pediatric lab other and (DIPG) Mueller the gliomas intrinsic pontine oncology. A key focus development the is characterization and of patient derived xenograft for diffuse models (PDX) Mueller Research Interests: Citation: Presentation Type: Location: S504 Presentation Date/Time: Saturday 2, June to 3:00PM 6:00PM Abstract link: Abstract #: Birgit Geoerger James Whitlock, Fox, Elizabeth Pooja Hingorani,W. Mark Russo, Dasgupta, Kohinoor Tseng, Lillian Mookerjee, Bijoyesh Authors*: (NF-1)–associated neurofibroma: plexiform A study phaseI/IIa Trametinib neurofibromatosis patients with pediatric type in 1 ______http://cancer.ucsf.edu/people/profiles/loh_mignon.3407 children, adolescents, young adults. and generation next for the of national ALL implementing trials and for supervising responsible 2015and in April starting for patients suspected of havingJMML. Dr. Loh Oncology ofChildren’s the currently is Group Chair (COG) ALL committee discoveries,these Dr. testing standard Loh as JMML diagnostictesting, nowutilized CLIA molecular is which established suppressor tumor gene. CBLdiscoveryof and the CBL ofdescriptions and PTPN11 mutations anewfamilial as From JMML focusedinto trials.in of clinical largely landscape JMML, work has genomic ondissecting the including Their that therapies can and beincorporated into assays (ALL) acute and myelomonocytic leukemia (JMML) lymphoblastic Loh Research Interests: Citation: Presentation Type: Location: S504 Presentation Date/Time: Saturday 2, June to 3:00PM 6:00PM Abstract link: Abstract #: Patrick Zweidler-McKay, A. Elizabeth L. Raetz, Mignon Loh, J. Naomi Winick, L.William Carroll, StephenHunger J. Briegel, Robert Nikki Hayashi, MGastier-Foster, Julie Andrew JCarroll, Nyla A.Asselin, R. Barbara Karen Heerema, Rabin, Authors*: t-cell malignancy diagnosed newly in COG nelarabine A testing AALL0434: randomized trial ______J Clin OncolJ Clin 36, 2018(suppl; abstr 10504) OncolJ Clin 36, 2018(suppl; abstr 10500) Geoffrey Brian McCowage, Brian Geoffrey Sabine Mueller, A. Christine Pratilas, Darren RHargrave, L. Christopher Moertel, Kimberly P.Kimberly Dunsmore, Winter, Stuart Devidas, Brent Meenakshi L. Wood, Natia Esiashvili, Nancy Eisenberg, 10504 10500 http://abstracts.asco.org/214/AbstView_214_214967.html http://abstracts.asco.org/214/AbstView_214_218959.html Oral AbstractSession Oral AbstractSession The LohThe focused biochemical has and genomic discoveries juvenile lab ontranslating in of Dr. laboratory The focuses research neuro- ontranslational pediatric in Mueller Sabine 31 *UCSF authors in bold in authors *UCSF

SATURDAY | JUNE 2, 2018 characteristics A apredictor breast as cancer model risk cancer of rate interval tumor and ______http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 formulti-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding a member Alliance &is is Committee novelto the to expand patients. available therapies director Shewas the of2016 the ASCO Breast Cancer Education Breast Cancer Program. Dr. order in academic large medical centers collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: D2 Hall Presentation Date/Time: 3, June Sunday 8:00 toAM 11:00 AM Abstract link: Abstract #: Yong Barriga, Susana Lin, George W. Sledge Authors*: breast cancer HR+, advanced with HER2- women for pre/perimenopausal Abemaciclib SUNDAY ______http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358 genomics data. Data Big Center NIH toTranslational Knowledge annotated Genomics, of standardization sharing facilitating worldwide breast aselection SNPs. and cancer genes ofsusceptibility for ~100known the susceptibility oneofPIs the She is evaluating to enhance newparadigms breast of targeted health. testing the genome Sheleads 100,000 for women 9 agent efficacy Network, I-SPY the in 2 of a BreastHealth PI the the Sheis Athena TRIAL. 150,000 study cohort women &resistance, response elicit to inhibitors understand utilized &howkinase also investigates is which kinases human ofpatient. genetic the the as makeup well laboratory as oftumor Her ofgenetic the the makeup onknowledge based van ‘t Veer Research Interests: Dr. van ’t Veer’s &advancing research medicine patient management focuses onpersonalized Citation: Presentation Type: Location: S404 Presentation Date/Time: 3, June Sunday 8:00 toAM 11:00 AM Abstract link: Abstract #: InvestigatorsAthena and Advocates, Laura Laura Esserman, van ‘t Veer Dreher, Nickolas Authors*: Irene Acerbi, Hadeler, Edward Kenji Shieh,Yiwey E. Michelle Melisko, J Clin OncolJ Clin 36, 2018(suppl; abstr 1002) J Clin OncolJ Clin 36, 2018(suppl; abstr 1506) Hope S. Neven, Hope Rugo,Patrick M. Sara Tolaney, HirojiToi, Iwata, Masakazu P. Matthew Goetz, Peter A. Kaufman, 1002 1506 http://abstracts.asco.org/214/AbstView_214_213753.html http://abstracts.asco.org/214/AbstView_214_213507.html Oral AbstractSession Oral AbstractSession | JUNE 3, 2018 3, JUNE 32

*UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/gi/chloe-atreya Clinical Trials Oncology, in Committee. Gastrointestinal of Oncologists, Society the of Clinical member American American Association of Cancer and Researchers Alliance for Development Award for Targeting Patient-Derived in of Colorectal Signaling Aberrant Cancer Models. Dr. Atreya a is K08Career Innovation of Health award 2017. in Institutes recipient the Cancer Sheis of aNational Institute/National Clinical Trials Oncology in FoundationInvestigator Award received she and aMarcus Program Precision in Medicine Cancer Conquer the Foundationof Oncology Society the of Clinical American Young Investigator Award, Alliance for treatment. of Dr. lifeby personalizing patient outcomes quality and Atreya recipient the is ofawards, numerous including focuses ofgenetics tumor to interplay response for onthe therapies and colorectal cancer, of goal improving the with Atreya Research Interests: Dr. cancer, gastrointestinal Atreya in specializes colorectal cancer. particularly research Her Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:3514 Li Wen Liang, Patricia Marinello, Tong Dai, H. Bert O’Neil Jean-Luc Van Laethem, Ravit Geva, Hiroya Taniguchi, Todd S. Crocenzi, Authors*: Evelyn ManishSharma, Chloe Atreya, ______http://cancer.ucsf.edu/people/profiles/venook_alan.3698 of the Committee Alliance for Clinical GI Trials CALGB) Oncology in (formerly from 2010-2015. to liver. the Dr. cooperative the of the within Chair as studies groupsVenook served authored and sixmajor and/or led has newest approaches the to therapies treatment and the of colorectal cancer, metastatic and tumors treating well as primary Comprehensive Family Diller Cancer Center. Helen UCSF effective the in regarded of expertise for use highly his is He Venook Research Interests: Dr. colorectal in renownedAlan expert liver and Venook cancers internationally an at is the Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:3570 Hayete,Boris P. Iya Khalil, Alan Venook O’Reilly, Rich,Kelly Lenz, Heinz-Josef Mary Niedzwiecki, Donna Eileen Fang-ShuOu, Latourelle, Jeanne Diane Wuest, Authors*: metastatic colorectal cancer (CRC) of CALGB modeling Causal drivers of network 80405(Alliance) to identify ______colorectal (MSI-H) high cance instability KEYNOTE-164: advanced for Pembrolizumab patients with microsatellite J Clin OncolJ Clin 36, 3514) 2018(suppl; abstr J Clin OncolJ Clin 36, 3570) 2018(suppl; abstr Dung Dung T. Le, Petr Kavan, Tae Won Kim, E. Matthew Burge, Eric Van Cutsem, Hiroki Hara, Patrick Boland, McKay Rahul K Das,Rahul Leon Furchtgott, Jeffrey A. Meyerhardt, Andrew B. Nixon, Innocenti, Federico Cunha, Daniel http://abstracts.asco.org/214/AbstView_214_220001.html http://abstracts.asco.org/214/AbstView_214_221911.html Poster Session Poster Session 33 r *UCSF authors in bold in authors *UCSF Luis A. Diaz,

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/people/profiles/venook_alan.3698 of the Committee Alliance for Clinical GI Trials CALGB) Oncology in (formerly from 2010-2015. to liver. the Dr. cooperative the of the within Chair as studies groupsVenook served authored and sixmajor and/or led has newest approachesthe to therapies treatment and the of colorectal cancer, metastatic and tumors treating well as primary Comprehensive Family Diller Cancer Center. Helen UCSF effective the in regarded of expertise for use highly his is He Venook Research Interests: Dr. colorectal in renownedAlan expert liver and Venook cancers internationally an at is the Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:4012 Kisha Mitchell,J. Boffa, KyleDaniel Perry, Wendy L Frankel,P. Alan O’Reilly, Venook, Mary Eileen David H. Ilson Authors*: of scan-directed PET therapy cancer for esophageal modality combined outcomes fromSurvival CALGB 80803(Alliance): A randomized phaseIItrial ______http://cancer.ucsf.edu/gi/michael-korn pathways.repair at developing for therapies cancers, transduction combination gastrointestinal of signal DNA and analysis onthe based cancers conducts and driven, conducts basket laboratory molecularly trials. His research disease-independent aimed Molecular Tumor Board. investigator newtreatments principal is exploring for He gastrointestinal of trials clinical cancers. Oncology of UCSF Molecular the Initiative of UCSF Chair the founding Furthermore, and leader the heis Research Interests:Korn Dr. aphysician-scientist of is focused gastrointestinal Korn science onthe management and Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:3577 Lenz,Heinz-Josef E. Mohamed Salem Wolfgang Korn, Michael Andreas Seeber, Jimmy J. Hwang, Philip Agop Philip, John Marshall, Edward S. Kim, Jagosky, Megan Authors*: Richard M. Goldberg, Derek Raghavan, Puccini, Alberto Anthony Frank Shields, David Arguello, (AYA)adults colorectal with cancer (CRC) adolescents young in and tumors of left- right-sided and analyses Molecular ______J Clin OncolJ Clin 36, 4012) 2018(suppl; abstr OncolJ Clin 36, 3577) 2018(suppl; abstr Karyn A.Karyn Goodman, Hall, Nathan Tanios S. Bekaii-Saab, Fang-ShuOu, Twohy, Erin O. Michael Meyers, http://abstracts.asco.org/214/AbstView_214_216065.html http://abstracts.asco.org/214/AbstView_214_221181.html Poster Session Poster Session 34 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/people/profiles/kelley_katie.3354 Cancer (TCGA) Genome Atlas liver cholangiocarcinoma cohorts. and cancers. projects, data and/or to multiple samples already successful has contributed bank This NCI/NHGRI including the data clinical from hepatobiliary patients with UCSF longitudinal with along bloodsamples plus samples tissue tumor cancer &Registry. collects family, Bank fresh &archival registry and Tissue bank Hepatobiliary This UCSF the Iinitiated development. in trials To advance complex/biologically-heterogeneous research &epidemiology this future in translational cancer patients. practice, our In weachieve consistently patient accrual have high and of arobust new clinical pipeline of novel advanced in agents&combinations hepatobiliary trials therapeutic for industry-sponsored PI numerous and tract cancers. carcinoma biliary hepatocellular and for several Study the Chair Iam investigator-initiated multicenter trials Research Interests: Myresearch developmentKelley clinical in focuses of newtreatments early onthe biomarkers and Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:4083 K. Abou-Alfa Ghassan Richard K. G. Do, F. Joanne Lee, Rodriguez Capanu, Chou, Ruiz, Mariam John Carmen Marinela Wilton, Renuka V. Iyer, Authors*: patients (pts) advanced carcinoma with hepatocellular (HCC) sorafenib (SORA) orwithout in with Phase (ENZA) 1B study of enzalutamide ______http://cancer.ucsf.edu/people/profiles/kelley_katie.3354 Cancer (TCGA) Genome Atlas liver cholangiocarcinoma cohorts. and cancers. projects, data and/or to multiple samples already successful has contributed bank This NCI/NHGRI including the data clinical from hepatobiliary patients with UCSF longitudinal with along bloodsamples plus samples tissue tumor cancer &Registry. collects family, Bank fresh &archival registry and Tissue bank Hepatobiliary This UCSF the Iinitiated development. in trials To advance complex/biologically-heterogeneous research &epidemiology this future in translational cancer patients. practice, our In weachieve consistently patient accrual have high and of arobust newclinical pipeline of novel advanced in agents&combinations hepatobiliary trials therapeutic for industry-sponsored PI numerous and tract cancers. carcinoma biliary hepatocellular and for several Study the Chair Iam investigator-initiated multicenter trials Research Interests: Myresearch developmentKelley clinical in focuses of newtreatments early onthe biomarkers and Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:4019 Stephen LamChan, Vincenzo Dadduzio, Hessel, Colin E.Anne Borgman-Hagey, Schwab, Gisela Kate Kelley Robin Cicin, Merle,Irfan Philippe Yen-Hsun Chen, Joong-Won Park, Blanc, Jean-Frédéric Luigi Bolondi, Josef Klümpen, Heinz Authors*: from trial Results randomized the phase 3CELESTIAL carcinoma havehepatocellular (HCC)who received sorafenib: prior (C)versus placebo patients (P)in (pts)Cabozantinib advanced with ______J Clin OncolJ Clin 36, 4083) 2018(suppl; abstr OncolJ Clin 36, 4019) 2018(suppl; abstr James J.James Harding, Kate Kelley, Robin BenjaminR. Tan, Emily Lobst, Chayma Boussayoud, E. Kerri Muenkel, K. Ghassan Abou-Alfa, Meyer,Tim Cheng, Ann-Lii Anthony El-Khoueiry, Lorenza Baek-Yeol Rimassa, Ryoo, http://abstracts.asco.org/214/AbstView_214_223645.html http://abstracts.asco.org/214/AbstView_214_226915.html Poster Session Poster Session 35 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/people/profiles/kelley_katie.3354 Cancer (TCGA) Genome Atlas liver cholangiocarcinoma cohorts. and cancers. projects, data and/or to multiple samples already successful has contributed bank This NCI/NHGRI including the data clinical from hepatobiliary patients with UCSF longitudinal with along bloodsamples plus samples tissue tumor cancer &Registry. collects family, Bank fresh &archival registry and Tissue bank Hepatobiliary This UCSF the Iinitiated development. in trials To advance complex/biologically-heterogeneous research &epidemiology this future in translational cancer patients. practice, our In weachieve consistently patient accrual have high and of arobust new clinical pipeline of novel advanced in agents&combinations hepatobiliary trials therapeutic for industry-sponsored PI numerous and tract cancers. carcinoma biliary hepatocellular and for several Study the Chair Iam investigator-initiated multicenter trials Research Interests: Myresearch developmentKelley clinical in focuses of newtreatments early onthe biomarkers and Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:4088 Steven Milwee, Anthony El-Khoueiry, Cheng, Ann-Lii Meyer,Tim K. Ghassan Abou-Alfa Ho Yeong Lim, DavidAri Baron, Francis Knox, Parnis, Jennifer Stéphane Cattan, Cheung Yau,Thomas Lougheed, Julie Kate Kelley, Robin Authors*: Baek-Yeol Ryoo, Merle, Joong-Won Philippe Park, Luigi Bolondi, StephenLamChan, placebo advanced (P)in carcinoma hepatocellular (HCC) (C)versus of cabozantinib trial systemic therapy phase 3CELESTIAL the in Outcomes patients in (pts) hadreceived who sorafenib prior only the (S)as ______http://cancer.ucsf.edu/people/profiles/kelley_katie.3354 Cancer (TCGA) Genome Atlas liver cholangiocarcinoma cohorts. and cancers. projects, data and/or to multiple samples already successful has contributed bank This NCI/NHGRI including the data clinical from hepatobiliary patients with UCSF longitudinal with along bloodsamples plus samples tissue tumor cancer &Registry. collects family, Bank fresh &archival registry and Tissue bank Hepatobiliary This UCSF the Iinitiated development. in trials To advance complex/biologically-heterogeneous research &epidemiology this future in translational cancer patients. practice, our In we achieve consistently patient accrual have high and of arobust newclinical pipeline of novel advanced in agents&combinations hepatobiliary trials therapeutic for industry-sponsored PI numerous and tract cancers. carcinoma biliary hepatocellular and for several Study the Chair Iam investigator-initiated multicenter trials Research Interests: Myresearch developmentKelley clinical in focuses of newtreatments early onthe biomarkers and Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:4087 Ngo,Zoe E. Zoe Quandt,Liu, Chienying P.Alan Venook, Lawrence Fong Gordan, Dozier John Andrew H. Ko, Pelin Cinar, Evelyn Chloe Atreya, Van Katherine Loon, Thomas Weber, Kate Kelley, Robin Authors*: Mitchell, Emily Spencer Behr, Hwang, Jimmy Keenan, EUmetsu, Bridget Sarah analyses outcomes biomarker and Clinical cancers factor colony (ABC): stimulating advanced in (GM-CSF) biliary macrophage granulocyte plus (PEM) of pembrolizumab 2trial Phase ______J Clin OncolJ Clin 36, 4088) 2018(suppl; abstr OncolJ Clin 36, 4087) 2018(suppl; abstr http://abstracts.asco.org/214/AbstView_214_226799.html http://abstracts.asco.org/214/AbstView_214_226371.html Poster Session Poster Session 36 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 preliminary survival data from survival aprospectivepreliminary phase IIstudy for locally advanced pancreatic(FFX) R0resection cancer rates (LAPC): and Potentially curative FOLFIRINOX and of combination TGF-b1 losartan inhibitor ______http://cancer.ucsf.edu/people/profiles/kelley_katie.3354 Cancer (TCGA) Genome Atlas liver cholangiocarcinoma cohorts. and cancers. projects, data and/or to multiple samples already successful has contributed bank This NCI/NHGRI including the data clinical fromhepatobiliary patients with UCSF longitudinal with along bloodsamples plus samples tissue tumor cancer &Registry. collects family, Bank fresh &archival registry and Tissue bank Hepatobiliary This UCSF the Iinitiated development. in trials To advance complex/biologically-heterogeneous research &epidemiology this future in translational cancer patients. practice, our In weachieve consistently patient accrual have high and of arobust newclinical pipeline of novel advanced in agents&combinations hepatobiliary trials therapeutic for industry-sponsored PI numerous and tract cancers. carcinoma biliary hepatocellular and for several Study the Chair Iam investigator-initiated multicenter trials Research Interests: Myresearch developmentKelley clinical in focuses of newtreatments early onthe biomarkers and Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:4090 Cheng, Ann-Lii Meyer,Tim Kate Kelley, Robin K. Abou-Alfa Ghassan Kim,Stefano Hun Chong Zhong-ZheLin, Vincent C. Tam, Mangeshkar, Milan Saswati Hazra, Anthony El-Khoueiry, Authors*: carcinomahepatocellular (HCC) (C)versus placebo patientscabozantinib (P)in (pts) advanced with of trial phase3CELESTIAL Outcomes the onagein based ______Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:4116 Theodore S. Hong DLillemoe,Keith F.Thomas DeLaney, K. Rakesh Jain, Jeffrey W. Clark, Yves Boucher, Castillo, Fernandez-del Carlos Lawrence Scott Blaszkowsky, Ferrone, Ryan David Parikh, Nipp, Raj Cristina Aparna Andrew X. Zhu, Goyal, Lipika Authors*: J Clin OncolJ Clin 36, 4090) 2018(suppl; abstr J Clin OncolJ Clin 36, 4116) 2018(suppl; abstr Lorenza Rimassa, Irfan Cicin,Lorenza Blanc, Irfan Jean-Frédéric Rimassa, Josef Klümpen, Heinz Zagonel, Vittorina Tran,Albert Janet E. Murphy, Jennifer Yon-Li Wo, David P. Ryan, Wenqing Jiang, Beow Y Yeap, Dan N. Duda, Jill Gabriel Allen, http://abstracts.asco.org/214/AbstView_214_227953.html http://abstracts.asco.org/214/AbstView_214_222259.html Poster Session Poster Session 37 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 in breast cancer. interested is developing Research in Interests: lab Our Munster novel strategies to overcome therapy hormone resistance Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:9018 David R. Spigel Pamela N. Munster, Jeffrey R. Infante, R. Manish Patel, Karen A. Autio, P. Kyriakos Papadopoulos, Aung Naing, Nashat Y. Gabrail, Authors*: NSCLC in anti-PD-1 and durability and treated pegilodecakin with Responses ______http://top.ucsf.edu/meet-the-team/medical-oncologists/thierry-marie-jahan,-md.aspx chemotherapy radiation. and/or with combination agentsorin single either as mesothelioma malignant cancer lung cell interest targetthoracic testing non-small in in therapies oncology aparticular has trials. He clinical sarcomas. Investigator Principal the soft and tissue is He suchmesothelioma, onnumerous as thoracic malignancies M. Research Interests: Jahan, Jahan Thierry M.D. treatment the in of arenowned medicaloncologist specializes is who Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:8515 Sapir,Inbal Campbell, Alice McDonald, Coreen Oei, Clawson, Roche,Carly Alicia Maria Dean A. Fennell Forster, Jahan, Scherpereel, Koczywas, Martin Arnaud Thierry B. Marianna Robert Cameron, Tobias Peikert, Authors*: inactivationBAP1 with (MM) relapsedorrefractory with mesothelioma adults in (R/R)malignant monotherapy tazemetostat as inhibitor 2,Phase study multicenter of EZH2 the ______J Clin OncolJ Clin 36, 9018) 2018(suppl; abstr J Clin OncolJ Clin 36, 8515) 2018(suppl; abstr Edward B. Garon, Schneider, Jeffrey Gary Deborah J.L. Wong, Raid Aljumaily, Wolfgang Korn, Michael Zauderer, Glass Marjorie Peter Szlosarek, Sylvestre Le Moulec, Popat, Sanjay Paul Taylor, David Planchard, http://abstracts.asco.org/214/AbstView_214_226447.html http://abstracts.asco.org/214/AbstView_214_214523.html Poster Session Poster Session Jonathan Jonathan Wade Goldman, Hung, PeterAnnie Van Vlasselaer, JosephLeveque, Oft, Martin 38 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://profiles.ucsf.edu/matthew.gubens Thymic Malignancy Interest Group. Oncology, Society of Clinical American Association for International Study the the of Lung Cancer International the and active evaluating approaches newimmunotherapy trials in thoracic in malignancies. Dr. of the amember is Gubens to clinic, factor the growth findings epidermal for receptor patients with especially mutations. (EGFR) group also The is have medicine, interest translational colleagues aspecial in his are and actively to translate laboratory-based working treatmentcancer. and lung research to strategies in studyHis newcompounds involves trials clinical designing and He thoracic carcinoma, other thymic and and malignancies, are including thymoma which rare ofmediastinum. tumors the athoracic is Research Interests: oncologist cancer, treats Gubens who Matthew lung Gubens patients with mesothelioma Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:9030 Suresh S. Ramalingam, Jensen, Erin Debra A. Kush, Edward B. Garon Joseph Paul Eder, Aggarwal, Balmanoukian, Charu Leora Sarkis Horn,Ani Patnaik,Amita A. Matthew Gubens, Authors*: from Results KEYNOTE-001 pembrolizumab: overall advanced for4-year patients with NSCLC survival treated with ______http://profiles.ucsf.edu/matthew.gubens Thymic Malignancy Interest Group. Oncology, Society of Clinical American Association for International Study the the of Lung Cancer International the and activealso evaluating approaches newimmunotherapy trials in thoracic in malignancies. Dr. of the amember is Gubens to clinic, factor the growth findings epidermal for receptor patients with especially mutations. (EGFR) groupThe is have medicine, interest translational colleagues aspecial in his are and actively to translate laboratory-based working treatment cancer. and lung research tostrategies in studyHis newcompounds involves trials clinical designing and He and thoracic carcinoma,other thymic and malignancies, are including thymoma which rare ofmediastinum. tumors the athoracic is Research Interests: oncologist cancer, treats Gubens who Matthew lung Gubens patients with mesothelioma Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:9026 Steven M. Keller, Leena Gandhi Yang,Chih-Hsin James Patnaik,Amita Steven Francis Powell, Renato G. Stevenson, James Martins, Jalal, ShadiaIbrahim Amit W. Panwalkar, Ryan D.Authors*: Gentzler, Corey J. Langer, Borghaei, M. Hossein Shirish Gadgeel, Vassiliki Papadimitrakopoulou, NSCLCnonsquamous therapy for advanced first-line as pembrolizumab plus carboplatin 24-month overall from G:Pemetrexed- survival KEYNOTE-021cohort ______J Clin OncolJ Clin 36, 9030) 2018(suppl; abstr OncolJ Clin 36, 9026) 2018(suppl; abstr Enriqueta Felip, Matthew David Hellmann, Rina Hui, EnricCarcereny, Natasha B. Leighl, Myung-Ju Ahn, http://abstracts.asco.org/214/AbstView_214_218423.html http://abstracts.asco.org/214/AbstView_214_217375.html Poster Session Poster Session Matthew A.Matthew Gubens, Lecia V. M. Sequist,Mark Awad, JosephFiore, Saraf, Sanatan 39 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/people/profiles/kelley_katie.3354 Cancer (TCGA) Genome Atlas liver cholangiocarcinoma cohorts. and cancers. projects, data and/or to multiple samples already successful has contributed bank This NCI/NHGRI including the data clinical from hepatobiliary patients with UCSF longitudinal with along bloodsamples plus samples tissue tumor cancer &Registry. collects family, Bank fresh &archival registry and Tissue bank Hepatobiliary This UCSF the Iinitiated development. in trials To advance complex/biologically-heterogeneous research &epidemiology this future in translational cancer patients. practice, our In weachieve consistently patient accrual have high and of arobust new clinical pipeline of novel advanced in agents&combinations hepatobiliary trials therapeutic for industry-sponsored PI numerous and tract cancers. carcinoma biliary hepatocellular and for several Study the Chair Iam investigator-initiated multicenter trials Research Interests: Myresearch developmentKelley clinical in focuses of newtreatments early onthe biomarkers and Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #: Jon Armstrong, Darilay,Annie Gordana Vlahovic, Negro,Alejandra Sangro Bruno Authors*: carcinomahepatocellular (HCC):HIMALAYA study tremelimumab unresectable(T) treatment patients in with first-line as A (D)and randomized, phase 3study multicenter of durvalumab ______http://www.bivonalab.net/ targetsand that provide rationale for we are to novel launching improve trials clinical patient survival. cancer of cancers) lung to discovery of other pathogenesis the newbiomarkers (and led has molecular the understanding putative integrated an drivers using approach molecular of tools. genetic pharmacologic and precision approachThis to novelto drivers identify ofinitiation, potential tumor progression, therapy and resistance. We functionally annotate the patients. individual drivers in ofgrowth tumor molecular characterizing the We data clinical and study patient samples targeted therapy cancers, solid of patients with cancer. including lung program Our functionally and focuses onidentifying tools of the precision to ResearchBivona Interests: uses improve medicine team Our and diagnosis molecular the Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #:9083 Phillipe Gui, James Fraser, Wolff, Alexander Rotow, Authors*: Julia Wei Wu, M. Collin Blakely, Richard B. Lanman, Victoria M. Raymond, Frederic J. Kaye, skipping mutation Concurrent adenocarcinoma a METexon alterations lung genomic in with 14 ______J Clin OncolJ Clin 36, 2018(suppl; abstr TPS4144) OncolJ Clin 36, 9083) 2018(suppl; abstr Ghassan K. Abou-Alfa, Stephen Lam Chan, Junji Furuse, Peter R. Galle, Kate Kelley, Robin Qin, Shukui TPS4144 http://abstracts.asco.org/214/AbstView_214_218661.html http://abstracts.asco.org/214/AbstView_214_217451.html Poster Session Poster Session Eric Eric Andrew Collisson, McCoach, Caroline Elizabeth Trever Grant Bivona 40 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 in breast cancer. interested is developing Research in Interests: lab Our Munster novel strategies to overcome therapy hormone resistance Citation: Presentation Type: Location: D1 Hall Presentation Date/Time: 3, June Sunday 9:45 toAM 11:15 AM Abstract link: Abstract #: Buerstatte,Nathan Sujata Arora, Pamela N. Munster Ursula A. Matulonis, Young B. N. Kim, Kathleen Moore, M. Elizabeth Swisher, Jeffrey Bruce Dezube, Jing Y. Wang, W.Robert Holloway, Linda Van Le, C. Jasgit Sachdev, Chapman-Davis, Eloise Gerardo Colon-Otero, Richard T. Penson, Authors*: or recurrent cancer ovarian from (ROC)—Results ROC cohort patients in (pts) advanced with triple-negativepembrolizumab breast cancer TOPACIO/Keynote-162 (NCT02657889): A phase + 1/2 study of niraparib ______http://cancer.ucsf.edu/gi/emily-bergsland treated since at UCSF 2004). patients 800+NET encompassing 2010and in advantage annotated outcomes (established oftaking database afully colleagues, lowgrade several and and neuroendocrine neoplasms, fostering high laboratory-based collaborations with progressivepatients with carcinoid tumors). Mycurrent research novel focuses treatment onassessing strategies for both Tumor Society. vs. of pazopanib placebo in for IItrial A021202 (arandomized study Phase chair also Iam ALLIANCE Tumors Panelmember, Guidelines of Board of the Directors amember and Neuroendocrine American for North the Neuroendocrine Tumor Task (NET) Committee, Neuroendocrine Force Steering aNCCN Gastrointestinal ofNCI the (NETs). onneuroendocrine tumors emphasis of an the fortherapies malignancies, with Chair gastrointestinal Iam Research Interests: MyresearchBergsland focused is development onthe of testing novel, and biologically based Citation: Presentation Type: Location: Hall A Presentation Date/Time: 3, June Sunday 8:00 toAM 11:30 AM Abstract link: Abstract #: Calabrese,Susan Grabowsky, Jennifer Ann Zhang, Jenna Lawrence K. Raj, Prabhakar Emily Bergsland Fong,Nitya Hooker, Claire Authors*: Jennifer A.Chan, neuroendocrine carcinomas extrapulmonary therapy previously in Pembrolizumab-based treated grade high ______J Clin OncolJ Clin 36, 2018(suppl; abstr 106) OncolJ Clin 36, 2018(suppl; abstr TPS4147)

Panagiotis Panagiotis A. Konstantinopoulos, Steven E. Waggoner, A. Gregory Vidal, Monica M. F. Mita,Gini Fleming, 106 TPS4147 http://abstracts.asco.org/214/AbstView_214_215001.html http://abstracts.asco.org/214/AbstView_214_222311.html Clinical Science Symposium Poster Session Rahul Raj Raj Aggarwal, Pelin Cinar,Rahul Tom Hope, Kolli, Kanti Zhang, Li 41 *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://profiles.ucsf.edu/sue.yom developing panels appropriatenational practice and use neckcancer. for and head guidelines of EBV-directed trial carcinoma. international on an Sheserves adjuvant for chemotherapy nasopharyngeal regimens cancer of and RTOGoropharyngeal for NRG-HN001, of lifechair 1707, successor trial. planned quality its the Sheis radiation. investigator therapy principal the for Sheis HPV-associated de-intensified in of NRG-HN002, trial anational of life, with of therapies quality novel making, combinations decision and patient-oriented systemicimaging-based and Yom Research Interests: Dr. Yom neck, and head in thoracic, expert an is cancers skin and conducts and research in Presentation Type: Location: Presentation Date/Time: 3, June Sunday 11:30 toAM 12:45PM Abstract link: Abstract #: Authors*: of Recent Studies Sense Making Treatment Strategies for Locoregionally Cancer: Advanced Nasopharyngeal ______http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784 factors. genetic and clinical risk known interact and survival that leukemia-free are associated variants with with several hostgermline identified has significant Global Alliance for ofPGRN-CGM Pharmacogenomics. the patientstransplantation among with work AML, part as This collaboration to of to toxicity of response and autologous studygenetic NIH-funded the determinants international an Large Lymphoma. B-cell Diffuse of outcomes patients clinical in with currently of is PI determinants He the significant redox ofexpression the gene in patterns work. drivers defense forpathway stress this identified has He as primary have the been statistical epidemiology expertise molecular his with combined experience clinical malignancies. His to prognosis cancer, treatment patients and in with response pertains it as (germline) hematologic especially and Andreadis Research Interests: Dr. of cancer interplay the Andreadis studies genetics pharmacogenetics traditional and Citation: Presentation Type: Location: E450 Presentation Date/Time: 3, June Sunday 9:45 toAM 12:45 PM Abstract link: Abstract #: Scott R. Solomon, Ghosh, M. Nilanjan Tina Xie, Albertson, Benhuai Jacob Garcia, Tanya Siddiqi Andres Forero-Torres, Michael Wang, David G. Maloney, Sehgal, Andreadis,Alison Charalambos Authors*: (JCAR017) R/Raggressive in of maraleucel lisocabtagene pivotal NHL trial NHL outcomes 001, clinical in safetyUpdated longterm and TRANSCEND ______J Clin OncolJ Clin 36, 2018(suppl; abstr 7505) Sue S. Sue Yom Jeremy S. Abramson, Leo I. Gordon, Palomba, Lunning, Lia Matthew JonE.Alexander Maria Arnason, 7505 http://abstracts.asco.org/214/AbstView_214_218963.html Meet the Professor the Meet Session Oral AbstractSession

42 Enkhtsetseg Purev,Enkhtsetseg *UCSF authors in bold in authors *UCSF

SUNDAY | JUNE 3, 2018 http://cancer.ucsf.edu/people/profiles/daud_adil.3622 cancers). other potentially responsive (and subsets of melanoma microenvironment depth in can and predict to non-response PD-1. We are currently novel exploring strategies for PD-1 non at UCSF, Krummel Max and we have Rosenblum Michael developed anovel that intra-tumoral profiles the assay Ihave involved melanoma. in been development the in of anti-PD-1 for my melanoma. colleagues With antibodies PD-1 treatment acombination as agentand with cancers many in immune an as inhibitors checkpoint other and work, 2005-2007. in onthis IL-12 Based trial clinical human in first the out electroporation carried and explored being is to response PD-1 biologyof immune the the understanding melanoma. in We developed IL- therapy12 gene melanoma in Daud Research Interests: group focused Our is at ondeveloping UCSF specifically agentsand newimmunotherapy Citation: Presentation Type: Location: Presentation Date/Time: 4, Monday June 8:00 toAM 11:00 AM A Abstract #:9506 Sharon, Elad A. Martin Cheever, Louise Suzanne Topalian, group trial CITN-09 Brent Allen Hanks, Thomas Olencki, BrianC. Boulmay, M Lisa Lundgren, Nirasha Ramchurren, Friedlander,Adam Philip Blanca Homet Andrew Moreno, Scott Brohl, Daud, Adil M. Harriet Kluger, Sunil A. Reddy, Melissa Amber Burgess, Authors*: therapy first-line as carcinoma cell receiving (aMCC) Merkel pembrolizumab advanced regression tumor overallDurable patients and (OS)in with survival ______http://cancer.ucsf.edu/people/profiles/daud_adil.3622 for PD-1 cancers). other potentially nonresponsive(and subsets of melanoma tumoral microenvironment depth in can and predict to non-response PD-1. We are currently novel exploring strategies at UCSF, Krummel Max and we have Rosenblum Michael developedcolleagues anovel that intra- profiles the assay Ihave involved melanoma. in been development the inhibitors in of anti-PD-1 for my melanoma. With antibodies PD-1 treatment acombination as agentand with explored cancersbeing many in immune an as checkpoint other and work, 2005-2007. in onthis IL-12 Based trial clinical human in first the out electroporation carried and is melanoma to response PD-1 biologyofimmune the understanding melanoma. in We developed IL- therapy12 gene in Daud Research Interests: group focused Our is at ondeveloping UCSF specifically agentsand newimmunotherapy Citation: Presentation Type: Location: Presentation Date/Time: 4, Monday June 8:00 toAM 11:00 AM Abstract link: Abstract #:9503 Christian U. Blank, Teresa M. Petrella, Omid Hamid, James Anderson, Clemens Krepler, Daud,Adil S. Matteo Nageatte Carlino, M. Ibrahim, Catriona McNeil, Lotem, Caroline Michal Robert M. James G. Larkin, Paul Lorigan, Neyns, Bart Authors*: KEYNOTE-006 in (ipi)-naive advanced melanoma patientsafter in (pts) ipilimumab 2-years with (pembro) outcomes and after of pembrolizumab cessation survival 4-year MONDAY ______bstract link: J Clin OncolJ Clin 36, 9506) 2018(suppl; abstr OncolJ Clin 36, 9503) 2018(suppl; abstr Arie Crown Arie Theater Crown Arie Theater Paul Nghiem, Shailender Bhatia,Paul Nghiem, Evan Shailender J. Lipson, Kudchadkar, Reiney Howard Sharfman,Ragini William Georgina V. Long, Jacob Schachter, Antoni Ribas, M.Ana Arance, Grob, Jean-Jacques Laurent Mortier, http://abstracts.asco.org/214/AbstView_214_213911.html http://abstracts.asco.org/214/AbstView_214_222303.html Oral AbstractSession Oral AbstractSession | JUNE 4, 2018 4, JUNE 43 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #:2583 Michelson, Rafe Martin, Glenn Shellooe, Eric Paul Severson, Pelayo, Michael David Sharma Sunil Karlin, Alan R. DavidWhisenant, S. Hong, Bui,Jonathan Nam Kummar, Shivaani Lynn G. Zhang, Chao Parikh, Feun, Raj Aparna Authors*: PLX8394 Phase inhibitor 1/2 precision study ofnext-generation medicine the BRAF ______http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 in breast cancer. interested is developing Research in Interests: lab Our Munster novel strategies to overcome therapy hormone resistance Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #:2578 Guan,Shanhong W. Isaiah Dimery, Borazanci Erkut J.Thomas George, Pamela Munster, Jordan Berlin, Gutierrez, Martin C.Alain Mita, Heather A. Wakelee, Selda Samakoglu, Authors*: relapsed/refractory patients in with tumors (R/R)solid durvalumab plus (BTK)A ibrutinib tyrosine kinase study inhibitor multicenter of Bruton’s the ______J Clin OncolJ Clin 36, 2583) 2018(suppl; abstr OncolJ Clin 36, 2578) 2018(suppl; abstr David S. Hong, Drew W. Rasco, H. Michael Veeder, J. Jason Luke, Chandler, Jason Balmanoukian, Sarkis Ani Filip Janku, N.Filip Ulka Vaishampayan, Vivek Bhatty, Minny Khemka, Jeffrey Sherman, Eric Jessica Tao, http://abstracts.asco.org/214/AbstView_214_215831.html http://abstracts.asco.org/214/AbstView_214_213567.html Poster Session Poster Session 45 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #: Richard Ambinder, Jeanette Y. Lee, Ronald T. Mitsuyasu, Noy Ariela A. DHarrington, Robert Baiocchi,Robert David Michael LeeAboulafia, Ratner, Durand, Christine Kaplan, Lawrence Authors*: HIV-related NHL AMC075: R-EPOCH aggressiveA in of vorinostat with randomized phaseIItrial ______http://cancer.ucsf.edu/people/profiles/smith_catherine.3369 ways to adaptations. circumvent evolutionary these to us interrogateallows can howtumors evolve selective the under pressure of cancer to us devise therapy allows and from patients have samples who that utilize studies undergone therapy translational real in time. with begins strategy This to problem the of cancer resistance, drug pathway thatultimate belief the onthe founded to improved cancer therapy prognosis. apoor conferring duplication mutations (ITD) We employ aprototypical to bench “bedside back” and approach Fms-like in Tyrosine (FLT3). Kinase-3 FLT3 ~30%of mutated in is AML, constitutively activating with FLT3 tandem internal treatment strategies for acute (AML). myeloid leukemia on We emphasis AML mutations have associated with aparticular Smith Research Interests: Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #: Deborah Lazzaretto, Jorge E. Cortes Authors*: prior or without 1st-generation FLT3 treatment (TKI) inhibitors tyrosine kinase patientsin (pts) FLT3-ITD–mutated with relapsed/refractory (mu) (R/R) AML with monotherapy of quizartinib Post phase2trials of two hoc exploratory analysis ______J Clin OncolJ Clin 36, 2018(suppl; abstr 7573) OncolJ Clin 36, 2018(suppl; abstr 7017) Juan Carlos Ramos, Carlos Juan Joseph A. Sparano, Page C. Moore, G. Erin Reid, Cesarman, Ethel Paul G. Rubinstein, Catherine Choy Smith, Levis, J. Mark 7573 7017 http://abstracts.asco.org/214/AbstView_214_225949.html http://abstracts.asco.org/214/AbstView_214_218771.html Poster Session Poster Session My laboratory focuses novel and Mylaboratory onidentification resistance of therapeutic mechanisms Koji Ishizuka, Ken Kobayashi, Meena Arunachalam, Yibin Wang, 46 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://labmed.ucsf.edu/wiita/ patients. myeloma to into benefit clinic of the models, goal moving the compounds with acrosspreclinical of vitro, immunotherapies asuite in and evaluation molecules of newsmall vivo, in patient and ex vivo to perform partners Translational academic Lab). industry with and Labworks Initiative (MMTI laboratory MMTI The addition,malignancies. In Myeloma Nancy Stephenand Grand Multiple UCSF the includes the Labalso Wiita quantitative proteomics spectrometry-based mass to discover targets newtherapeutic hematologic basicbiologyand in To gap,attempt knowledge chemical biology, to this bridge engineering, the of acombination genome Lab uses Wiita and remodel cancer the proteome,perturbations fact despitethe biological function. all thatout proteins actually carry of cancer the transcriptome. and genome Less known, is however, alterations therapeutic howgenomic and about cancer in Research Interests: effort research directedWiita Significant been has composition the towards understanding Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #:8034 Wiita, Arun Payal Pratap, DuyPham, Udaya Rangaswamy, Schellenberger, Ute Shah, Nathan Nina Trinklein, Ugamraj, Harshad Authors*: antibody targeting BCMA for myeloma treatment the of multiple Pre-clinical development of TNB-383B, human T-cell afully bispecific engaging ______http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin to therapeutics.response anti-MM address genetics the of MM, role the ofmicroenvironment for the patient selection discoveryof as biomarkers and well as investigatorprincipal to designed studies onover research (PI) clinical includestranslational trials. His clinical also 25MM the been has and Research Interests: hematological Dr. in malignancies Martin expert aleading is Martin Thomas Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #:8014 Noa Biran, Jeffrey Wolf, Samir S. Parekh, Pamela N. Munster, Deepu Madduri, Frank Campana, G. Thomas Martin Authors*: (RRMM) myeloma refractory relapsedand in +carfilzomib multiple I-bstudy ofPhase isatuximab ______J Clin OncolJ Clin 36, 8034) 2018(suppl; abstr J Clin OncolJ Clin 36, 8014) 2018(suppl; abstr Ben Buelow,Ben PriyaChoudry, Clarke, KevinStarlynn Dang, Laura Davison, Force Shelley Aldred, Harris, Katherine Ajai Chari, Ryan Richter, Joshua Ajai Shah, Nina Sandy Wai Kuan Wong, J. Jagannath, Sundar Hearn Cho, Wim VanWim Schooten http://abstracts.asco.org/214/AbstView_214_228187.html http://abstracts.asco.org/214/AbstView_214_219981.html Poster Session Poster Session 47 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 in breast cancer. interested is developing Research in Interests: lab Our Munster novel strategies to overcome therapy hormone resistance Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #: J. Marc Pipas, Sharon Chen, Sergio Santillana, Vasileios Askoxylakis Authors*: tumors solid patients in with MM-310 A phase 1 study evaluating safety, the activity of preliminary and pharmacology ______http://cancer.ucsf.edu/gi/katherine-van-loon oncology. of global academic field focused is and career onproviding investigators to early interests mentoring emerging research and the in with training Center, of research projects capacity-building oversees and she portfolio alarge countries middle-income low and in of Africa. role her In Director as Cancer Comprehensive Family of Global the Program Diller Cancer Helen at UCSF’s corridor carcinoma eastern cell the along squamous of esophageal determinants genetic and molecular exposures and in RoadCancerOcean Institute Tanzania, Investigator Principal the is she of several environmental to identify studies Sciences and and Allied of Health University (AfrECC). Muhimbili Cancer collaboration In with Consortium Esophageal incidence high disproportionately cancerthe of of esophageal the East Africa, in member African afounding is she and Van Loon Research Interests: Dr. Van Loon oncologist. agastrointestinal is research Her focused is onunderstanding Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #: Mwatsuma Mwachiro,Michael Paciorek, Alan Zhang, Li Van Katherine Loon RebeccaAuthors*: Deboer, NBhatta, Buckle, Geoffrey Dharma JuXu, Melody Kennell-Heiling, Stephanie oncology of global academicemerging field career development and offor amodel training the Implementation in ______J Clin OncolJ Clin 36, 2018(suppl; abstr TPS2604) J Clin OncolJ Clin 36, 2018(suppl; abstr 11008) Marc S.Ernstoff,Marc Frank WenYung-ChinMa, Tsai, Wee 11008 TPS2604 http://abstracts.asco.org/214/AbstView_214_216395.html http://abstracts.asco.org/214/AbstView_214_222347.html Poster Session Poster Session 48 Pamela N. Munster, Zhang, Tian Walid Kamoun, *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin to therapeutics.response anti-MM address genetics the of MM, role the ofmicroenvironment for the patient selection discoveryof as biomarkers and well as investigatorprincipal to designed studies onover research (PI) clinical includestranslational trials. His clinical also 25MM the been has and Research Interests: hematological Dr. in malignancies Martin expert aleading is Martin Thomas Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #: FaconThierry Authors*: (NDMM) myeloma multiple diagnosed newly patients (pts) (R), (d)vs with dexamethasone transplant-ineligible and VRd in (V), bortezomib lenalidomide plus Isatuximab study design: III(IMROZ) Phase ______http://cancer.ucsf.edu/people/profiles/shah_nina.8258 for myeloma. vaccines, cell-based interested dendritic also in adoptive combinations T novel and therapies cell immunomodulatory transplantation. dose setting stemcell the ofchemotherapy autologous in high and cells derived natural killer Sheis for cord trial cord clinical blood umbilical novel conducted platformbloodand using cell natural killer afirst-in-human Research Interests: therapy myeloma.developedShah Dr. Shehas for a multiple cellular in expert an is Shah Nina Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #: John M. Burke, Leslie Popplewell, Cheung,L. G. Shannon Julee Matheny, Thomas Martin, Paul John Leonard, Molina Arturo Authors*: B-cell malignancies of STRO-001, conjugate, anti-CD74 antibody drug an advanced patients in with A phase 1 open-label, safety, pharmacokinetic, efficacy study preliminary and ______J Clin OncolJ Clin 36, 2018(suppl; abstr TPS8055) OncolJ Clin 36, 2018(suppl; abstr TPS7586) Robert Z. Orlowski, Hartmut Goldschmidt, Cavo, Z. Michele Orlowski,Robert Hartmut G. Paux, Thomas Gautier Martin, Oprea, Corina Amrita Y.Krishnan, TPS8055 TPS7586 http://abstracts.asco.org/214/AbstView_214_215475.html http://abstracts.asco.org/214/AbstView_214_212053.html Poster Session Poster Session Alexander I. Shah, Nina Alexander Spira, L. Jonathan Kaufman, Niesvizky, Ruben Shah, Nirav Niranjan 49 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 Authors*: trial phase 3Heritage after therapy: combination Toxicity, efficacy, from the immunogenicity and monotherapy monotherapy versus trastuzumab trastuzumab-dkst Biosimilar ______http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin to therapeutics.response anti-MM address genetics the of MM, role the ofmicroenvironment for the patient selection discoveryof as biomarkers and well as investigatorprincipal to designed studies onover research (PI) clinical includestranslational trials. His clinical also 25MM the been has and Research Interests: hematological Dr. in malignancies Martin expert aleading is Martin Thomas Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June 8:00 toAM 11:30 AM Abstract link: Abstract #: Philippe Moreau G.Authors*: Thomas Meletios Martin, A. Dimopoulos, Kwee Yong, JosephMikhael, Risse, Marie-Laure Gaëlle Asset, multiple myeloma (RRMM) relapsed/refractory patients (Kd)vsKdin with dexamethasone and carfilzomib plus Isatuximab study design: III(IKEMA) Phase ______http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 foreducational breast session cancer from patients, bay throughout the &friends area. families trial. ISPY2 for multi-center neoadjuvant safety the committee At UCSF, Dr. BreastForum, the abimonthly Rugoruns negative group. triple the working where co-leads she the novel onthe Consortium leads Sheis and agentscommittee Breast Cancer oftranslational Research the of the member meeting, afounding amember Alliance &is is Committee novelto the to expand patients. available therapies director Shewasthe of2016 the ASCO BreastCancer Education Breast Cancer Program. Dr. order in academic large medicalcenters collaborations with &consortia numerous Rugohas to improve onstudies works She also &late care stageBCpatients, supportive for early UCSF’s Advanced includingwith focusing novel oncombining targeted to therapeutics improve &late stagebreast treatment cancer the ofearly both (BC). Rugo Research Interests: Dr. Rugo, Director of Breast Oncology &Clinical Trials Education, trials clinical onmultiple PI is Citation: Presentation Type: Location: D1 Hall Presentation Date/Time: 4, Monday June 9:45 toAM 11:15 AM Abstract link: Abstract #: Abhijit Barve, S. Hope Rugo Ray,Sirshendu F. Cornelius Waller, Bronchud, Hernandez Miguel Jay Herson, Loganathan, Subramanian Luisa T.Maria Akewanlop,Abesamis-Tiambeng, Charuwan Ihor Vynnychenko, Virote Sriuranpong, J Clin OncolJ Clin 36, 2018(suppl; abstr TPS8060) J Clin OncolJ Clin 36, 2018(suppl; abstr 110) Aleksei Manikhas, Eduardo J. Pennella, Igor Bondarenko, Guzel Mukhametshina, 110 TPS8060 http://abstracts.asco.org/214/AbstView_214_216181.html http://abstracts.asco.org/214/AbstView_214_224369.html Poster Session Clinical Science Symposium 50 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://cancer.ucsf.edu/people/profiles/daud_adil.3622 cancers). other potentially non responsive (and subsets of melanoma microenvironment depth in can and predict to non-response PD-1. We are currently novel exploring strategies for PD-1 at UCSF, Krummel Max and we have Rosenblum Michael developed anovel that intra-tumoral profiles the assay Ihave involved melanoma. in been development the in of anti-PD-1 for my melanoma. colleagues With antibodies PD-1 treatment acombination as agentand with cancers many in immune an as inhibitors checkpoint other and work, 2005-2007. in onthis IL-12 Based trial clinical human in first the out electroporation carried and explored being is to response PD-1 biologyofimmune the the understanding melanoma. in We developed IL- therapy12 gene melanoma in Daud Research Interests: group focused Our is at ondeveloping UCSF specifically agentsand newimmunotherapy Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #:9516 M.Hassane Zarour, Anthony M. Joshua, Jensen, Erin Nageatte Ibrahim, Sama Ahsan, Antoni Ribas Peter Hersey, Richard Wayne Joseph, Jeffrey S. Weber, Stefania Dronca, Roxana Tara C. Mitchell, Patnaik,Amita Authors*: with pembrolizumab (pembro) in KEYNOTE-001 outcomes treated patients in (pts) advanced survival with melanoma 5-year ______http://cancer.ucsf.edu/people/profiles/daud_adil.3622 cancers). other potentially non responsive(and subsets of melanoma microenvironment depth in can and predict to non-response PD-1. We are currently novel exploring strategies for PD-1 at UCSF, Krummel Max and we have Rosenblum Michael developed anovel that intra-tumoral profiles the assay Ihave involved melanoma. in been development the in of anti-PD-1 for my melanoma. colleagues With antibodies PD-1 treatment acombination as agentand with cancers many in immune an as inhibitors checkpoint other and work, 2005-2007. in onthis IL-12 Based trial clinical human in first the out electroporation carried and explored being is to response PD-1 biologyof immune the understanding melanoma. in We developed IL- therapy12 gene melanoma in Daud Research Interests: group focusedOur is at ondeveloping UCSF specifically agentsand newimmunotherapy Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #:9511 D. Serbest, Karl Gul Lewis Daud, N. Mansoor Adil Authors*: Saleh, Hu, James Scott Jonathan Bleeker, Riese, John Matthew Meier, Roland Zhou, Li study of ECHO-204 the phase2results Updated Epacadostat for advanced nivolumab plus melanoma: ______J Clin OncolJ Clin 36, 9516) 2018(suppl; abstr OncolJ Clin 36, 9511) 2018(suppl; abstr Omid Hamid,Omid Caroline Daud, Adil Robert, F. StephenHodi, Wen-Jen Hwu, Richard Kefford, JeddD. Wolchok, http://abstracts.asco.org/214/AbstView_214_219723.html http://abstracts.asco.org/214/AbstView_214_213511.html Poster Session Poster Session 51 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://cancer.ucsf.edu/people/profiles/arron_sarah.3338 area of cancer. the skin in companies for pharmaceutical matter expert space, dermatology the in active an trials. Sheis companies asubject as interventional serves and for startup consultant investigator-initiated and industry-sponsored onmultiple PI the been has and Research Unit Clinical Dermatology UCSF carcinoma.Director cell as focused squamous Sheserves metagenomics genomicsand of onthe cutaneous of the postdoctoraland viral research metagenomics bioinformatics. research in and atranslational training laboratory Sheruns Informatics. Clinical and Dermatology in Dr. Micrographic board and certified Mohs in Surgery Arron aPh.D. has virology in FranciscoSan Micrographic Francisco of at Chief Mohs San and the Surgery VA MedicalCenter. trained fellowship Sheis Arron Research Interests: Sarah an Arron is Associate Professor of of atCalifornia, Dermatology University the Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #:9577 Authors*: of recurrence risk carcinomacell ahigh (cSCC) patients with signature for improvedA risk multi-gene identification squamous of cutaneous ______http://cancer.ucsf.edu/people/profiles/daud_adil.3622 cancers). other potentially non responsive(and subsets of melanoma microenvironment depth in can and predict to non-response PD-1. We are currently novel exploring strategies for PD-1 at UCSF, Krummel Max and we have Rosenblum Michael developed anovel that intra-tumoral profiles the assay Ihave involved melanoma. in been development the in of anti-PD-1 for my melanoma. colleagues With antibodies PD-1 treatment acombination as agentand with cancers many in immune an as inhibitors checkpoint other and work, 2005-2007. in onthis IL-12 Based trial clinical human in first the out electroporation carried and explored being is to response PD-1 biologyof immune the understanding melanoma. in We developed IL- therapy12 gene melanoma in Daud Research Interests: group focused Our is at ondeveloping UCSF specifically agentsand newimmunotherapy Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #:9541 Neves, Izar Rogerio Daud, Adil Hung T. Khong, Richard S. Ungerleider, Maki Tanaka Authors*: metastatic melanoma stageIIIb-IV treatmentcombination patients unresectable in with or replication-competent HSV-1 oncolytic immunotherapy, ipilimumab and of HF10, for trial aphase IImulticenter a genetic and Efficacy analysis ______J Clin OncolJ Clin 36, 9577) 2018(suppl; abstr J Clin OncolJ Clin 36, 9541) 2018(suppl; abstr Sarah T Arron, Arron, T Schmults, Sarah Chrysalyne I. Andtbacka, Merrick Ross, Ingemar S. Hans Sanjiv H. Matthew Robert Agarwala, Taylor, John T. Vetto, http://abstracts.asco.org/214/AbstView_214_228533.html http://abstracts.asco.org/214/AbstView_214_229247.html Poster Session Poster Session Ashley Ashley Wysong, R. Kyle Covington, W. Robert Cook, Newman Jason 52 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372 of life.patient to quality howbest treat studies bloodcancers Shealso patients. older in interested process cancer the in in treatment making impact of the decision and particularly ofis cancer treatment on myeloproliferative myelodysplasia and of lymphoma, leukemia, disorders, research, her myeloma. In multiple and she Research Interests:Olin Dr. treatment the and transplantation (BMT) bonemarrow adult in Rebecca specializes Olin Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #: Lawrence D. N. Kaplan, Gabriel Mannis, Aaron Logan, Damon, Lloyd Earl Chiung-Yu Huang, Rebecca L. Olin T. Mariam Authors*: Nawas, Andreadis, Charalambos G.Thomas Jeffrey Martin, Lee Wolf, Weiyun Z. Ai, (AutoHCT) hematopoietic transplant autologous cell undergoing adults Impact functional of onoverall patient older reported in limitation survival ______http://cancer.ucsf.edu/people/profiles/dixit_niharika.7394 care impactthe plans. of survivorship interested investigating in science implementation an approach safety in net care assessing and delivery to survivorship have of and my patients cancer. arehospital, several additionto underserved in their majority the challenges and Iam Research Interests:Dixit Myresearch cancer at and Iwork asafety interestcancer net disparities. in is survivorship Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #: Barbara Cicerelli, Anna Napoles Sarkar, Dixit, Nancy Burke, Niharika Authors*: Urmimala Rodriguez, Gladys Judy Quan, Devore, Joana colon cancer survivors self-efficacy for and breastPCPs for and caring knowledge ______J Clin OncolJ Clin 36, 2018(suppl; abstr 10030) J Clin OncolJ Clin 36, 2018(suppl; abstr 10083) 10030 10083 http://abstracts.asco.org/214/AbstView_214_209967.html http://abstracts.asco.org/214/AbstView_214_226265.html Poster Session Poster Session 53 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358 genomics data. Data Big Center NIH toTranslational Knowledge annotated Genomics, of standardization sharing facilitating worldwide breast aselection SNPs. and cancer genes ofsusceptibility for ~100known the susceptibility oneofPIs the Sheis evaluating to enhance newparadigms breast of targeted health. testing the genome Sheleads 100,000 for women 9 agent efficacy Network, I-SPY the in 2 of a Breast Health PI the the Sheis Athena TRIAL. 150,000 study cohort women &resistance, response elicit to inhibitors understand utilized &howkinase also investigates is which kinases human ofpatient. genetic the the as makeup well laboratory as of tumor Her ofgenetic the the makeup onknowledge based van ‘t Veer Research Interests: Dr. van ’t Veer’s &advancing research medicine patient management focuses onpersonalized Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #: Gillian L. Hirst, Laura Esserman, A. Donald Berry, Authors*: I-SPY patients the in 2trial HER2+ in trebananib inhibitor Association of activation levels to angiogenesis response of the with TIE2 ______http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358 annotated genomics data. Data Big Center for NIH the toTranslationalPIs Knowledge Genomics, of standardization sharing facilitating worldwide forwomen 9breast aselection SNPs. and cancer genes ofsusceptibility ~100known susceptibility oneof the Sheis study evaluating to enhancecohort newparadigms breast of targeted health. testing the genome Sheleads 100,000 agentefficacy Network, I-SPY the understand in 2 of a Breast Health PI the the Sheis Athena TRIAL. 150,000 women &resistance, response elicit to inhibitors utilized &howkinase also investigates is which laboratory kinases Her human ofpatient. genetic the the as makeup well as oftumor ofgenetic the the makeup onknowledge based management van ‘t Veer Research Interests: Dr. van ’t Veer’s &advancing research medicine patient focuses onpersonalized Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #: Gillian L. Hirst, Laura Esserman, Authors*: patients HER2+ and HER2- both in I-SPY the MK2206in 2trial inhibitor substrates of to kinase predictAKT Phosphorylation to response the AKT ______J Clin OncolJ Clin 36, 2018(suppl; abstr 12103) OncolJ Clin 36, 2018(suppl; abstr 12099) Rosa Isabela Gallagher, Isabela Rosa Dianne Julia Wulfkuhle, Yau, Christina M Denise Wolf,Swigart, Brown Lamorna Wulfkuhle,Dianne Julia 12103 12099 http://abstracts.asco.org/214/AbstView_214_223425.html http://abstracts.asco.org/214/AbstView_214_221641.html Poster Session Poster Session Denise M Wolf, Yau, Denise Christina Gallagher, Isela Rosa Brown Swigart, Lamorna Donald Donald A. Berry, Laura van ‘t Veer, Petricoin Emanuel Laura van ‘t Veer, Petricoin Emanuel 54 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://profiles.ucsf.edu/sue.yom developing panels appropriatenational practice and use neckcancer. for and head guidelines of EBV-directed trial carcinoma. international on an Sheserves adjuvant for chemotherapy nasopharyngeal regimens cancer of and RTOGoropharyngeal for NRG-HN001, of lifechair 1707, successor trial. planned quality its the Sheis radiation. investigator therapy principal the for Sheis HPV-associated de-intensified in of NRG-HN002, trial anational of life, with of therapies quality novel making, combinations decision and patient-oriented systemic imaging-based and Yom Research Interests: Dr. Yom neck, and head in thoracic, expert an is cancers skin and conducts and research in Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #: S. Sue Yom, Authors*: carcinomaadvanced cell (Alliance merkel A091605) stereotactic versus antibody plus alone anti-PD1 body radiation therapy in A randomized phaseIIstudy of antibody[MK-3475(Pembrolizumab)] anti-PD1 ______http://cancer.ucsf.edu/people/profiles/alvarez_edwin.8285 forof Division Gynecologic the Oncology trials clinical at UCSF. invasive minimally gynecologic and oncology open both complicated and gynecologic surgery. director as serves He of cancer,ovarian cancer, cervical cancer cancers reproductive other endometrial and offemale the system. performs He UCSF Helen Diller Family Comprehensive Cancer Center. focus His primary is the surgical and medical treatment of Alvarez Research Interests: Dr. agynecologicAlvarez Edwin oncologist is Alexander and Associate Professor at the Citation: Presentation Type: Location: Hall A Presentation Date/Time: 4, Monday June to1:15 PM 4:45PM Abstract link: Abstract #: J.Bradley Monk Stephanie Lheureux, Danny Rischin, Alessandro Santin, Minjie Feng, Mathias, Melissa Matthew G. Fury, Israel Lowy, Authors*: ≥ of cemiplimab, anti-PD-1, an versus investigator’s choice chemotherapy (IC) in GOG 3016/ENGOT-cx9: open-label,An multi-national, randomized, phase3trial ______2 line recurrent2 line ormetastatic cancer cervical J Clin OncolJ Clin 36, 2018(suppl; abstr TPS9599) OncolJ Clin 36, 2018(suppl; abstr TPS5600) Krishnansu Sujata Sujata Tewari,Krishnansu Ignace Vergote, Oaknin,Ana Edwin Alvarez, Jason J. Luke, Steven J. Chmura, Jacob B Allred, Joseph Salama, Kamel Hania A Al-Hallaq, Hsu, Charles TPS9599 TPS5600 Mark Kozloff,Mark Pamela N. Munster, K. Schwartz Gary http://abstracts.asco.org/214/AbstView_214_216845.html http://abstracts.asco.org/214/AbstView_214_217301.html Poster Session Poster Session 55 Dana Meredith Chase, Stephanie Gaillard, *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 http://cancer.ucsf.edu/people/profiles/small_eric.3671 treatment resistance orprevented, maybedelayed profoundly improving care the affected of men fatal disease. by this progression. them, disease expectedallowing such is “adaptive” inhibiting it and that Byidentifying mechanisms therapy for prostate cancer processes occurs to evade ultimately cancer therapies, exploit commoncellular when the cells Research Interests: Dr.Small current research that Small’s resistance program hypothesis Eric the to in hormonal based is Citation: Presentation Type: Location: D1 Hall Presentation Date/Time: 4, Monday June to 3:00PM 6:00PM Abstract link: Abstract #:LBA5005 Jay Small, Tannock,Eric Ian Kelly Kevin William Logothetis,Christopher David S. I. Celestia Fizazi, Higano, Quinn, Karim J. Daniel George, J. Michael Morris, N.Kim Chi, S. Johann De Bono,Thompson, Fandi, Abderrahim C.Murchie John Ian Araujo, A. Mario Eisenberger, Authors*: metastatic castration-resistant prostate cancer (mCRPC) between CaucasianAfrican-American with and Overall (C)men survival (AA) ______http://cancer.ucsf.edu/people/profiles/hope_thomas.7336 (DWI). weighted imaging parameters suchdiffusion as interpretation imaging and MR rely in likely onchanges will role,important to uptake response change treatment as will of non-FDG tracers ways in that clear are notimmediately tumor. of primary have the likely setting metastatic will evenimaging the of an patients In with disease, more PET/MRI prostatectomy lowrisk in out PSMA Ga-68 MR using and carrying patients where we are evaluating of PET/MRI use the of cancers. staging the in aid astudy parameters we will is PET are ofand combination MR Moststraightforward the neuroendocrine prostate PSMA orderand agentsin PET to distinguish based cancer from adenocarcinoma. Ibelieve that I have somatostatin interested successfully using brought receptor also in also am and to PSMA UCSF Ga-68 imaging DOTA-TOCdeveloped gallium-68 the program imaging FDA onthe for staging, PI neuroendocrine tumor the am and IND. Research Interests:Hope Myresearch program novel and cancer focused MRI tracers. is PET using onimaging Ihave Citation: Presentation Type: Location: D1 Hall Presentation Date/Time: 4, Monday June to 3:00PM 6:00PM Abstract link: Abstract #:5001 Johannes Czernin, Matthias Eiber Hope,A Rettig,Matthew Thomas Authors*: results from aphase 2/3prospective trial Accuracy PET/CT of 68Ga-PSMA11 onrecurrent prostate cancer: Preliminary ______J Clin OncolJ Clin 36, LBA5005) 2018(suppl; abstr OncolJ Clin 36, 5001) 2018(suppl; abstr

Susan Halabi, Sandipan Dutta, Catherine M. Dutta, Catherine Halabi, Sandipan Susan Tangen, Rosenthal, Peter Mark Daniel Petrylak, Wolfgang Fendler, Nickols, George Evan Nicholas Gartmann, Reiter, Robert Calais, Jeremie Jeannine http://abstracts.asco.org/214/AbstView_214_211593.html http://abstracts.asco.org/214/AbstView_214_222949.html Oral AbstractSession Oral AbstractSession Roger Slavik,Roger Pawan Gupta, Andrew Quon,Allen-Auerbach, Martin Herrmann, Ken 56 *UCSF authors in bold in authors *UCSF

MONDAY | JUNE 4, 2018 Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer

Authors*: Ran Ran, Wenfa Huang, Shao Lin, Yunyun Niu, Hope S. Rugo, Weiyao Kong, Shiping Bo, Sijia Lu, Huiping Li

Abstract #: e13018 Abstract link: http://abstracts.asco.org/214/AbstView_214_226701.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e13018)

Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSF’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the translational Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee and leads the safety committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area. http://cancer.ucsf.edu/people/profiles/rugo_hope.3648

______

Meta-analysis reveals multiple drivers of colorectal cancer pathogenesis

Authors*: Kamal Khorfan, Jihad Aljabban, Laraib Safeer, Hisham Aljabban, Maryam Panahiazar, Anne M. Noonan, Dexter Hadley

Abstract #: e15601 Abstract link: http://abstracts.asco.org/214/AbstView_214_229665.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e15601)

Hadley Research Interests: Dr. Hadley’s expertise is in translating big data into precision medicine and digital health. His research generates, annotates, and ultimately reasons over large multi-modal data stores to identify novel biomarkers and potential therapeutics for disease. His early work resulted in a successful precision medicine clinical trial for ADHD a first-in-class, non-stimulant neuromodulator to be targeted across the neuropsychiatric disease spectrum. More recently, his laboratory was funded by the NIH Big Data to Knowledge initiative to develop the stargeo.org online portal to crowd- source annotations of open genomics big data that allows users to discover the functional genes and biological pathways that are defective in disease. Dr. Hadley also develops state-of-the-art data driven models of clinical intelligence that drive clinical applications to more precisely screen, diagnose, and manage disease. The end point of his work is rapid proofs of concept clinical trials in humans that translate into better patient outcomes and reduced morbidity and mortality across the spectrum of disease. http://cancer.ucsf.edu/people/profiles/hadley_dexter.8139

______

57 *UCSF authors in bold Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8)

Authors*: Ghassan K. Abou-Alfa, Qian Shi, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjamin R. Tan, Petr Kavan, Rakesh Goel, Philip Edward Lammers, Tanios S. Bekaii-Saab, Vincent C. Tam, Lakshmi Rajdev, Robin Kate Kelley, Abby B. Siegel, Tyler Zemla, Imane H. El Dika, Alan P. Venook, Monica M. Bertagnolli, Jeffrey A. Meyerhardt, Eileen Mary O’Reilly

Abstract #: e16107 Abstract link: http://abstracts.asco.org/214/AbstView_214_216837.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e16107)

Venook Research Interests: Dr. Alan Venook is an internationally renowned expert in colorectal and liver cancers at the UCSF Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating primary and metastatic tumors to the liver. Dr. Venook has led and/or authored six major studies within the cooperative groups and served as Chair of the GI Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB) from 2010-2015. http://cancer.ucsf.edu/people/profiles/venook_alan.3698

______

Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis

Authors*: Quisette Janssen, Stefan Buettner, Mustafa Suker, Georgios A Margonis, Alessandro Paniccia, Bassel F. El-Rayes, Nathan Bahary, Ian Chau, Peter Joel Hosein, Andrew H. Ko, Jill Lacy, Nigel Jamieson, Christoph Tinchon, Kyu-Pyo Kim, Marc G. Besselink, Johanna Wilmink, Marjolein Y.V. Homs, Casper H.J. van Eijck, Matthew H. G. Katz, Bas Groot Koerkamp

Abstract #: e16207 Abstract link: http://abstracts.asco.org/214/AbstView_214_218185.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e16207)

Ko Research Interests: My primary clinical and research interests focus on gastrointestinal malignancies, with a particular emphasis on pancreatic and gastroesophageal cancers. I have received research funding from the National Cancer Institute, a career development award from the American Society of Clinical Oncology (ASCO), and have partnered with multiple industry collaborators in developing and evaluating a variety of new therapeutic agents ranging from novel cytotoxics to molecularly targeted agents to immunotherapies. My interests also include identifying individual patient/ tumor characteristics that influence prognosis and response to specific therapies, including both tissue- and blood-based biomarkers. I have served on the scientific program committee, grants committee, and specialty editorial board for the American Society of Clinical Oncology (ASCO), am currently an Associate Editor for the Journal of Clinical Oncology, and serve as a member of NCI’s Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee. http://cancer.ucsf.edu/people/profiles/ko_andrew.3444

______58 *UCSF authors in bold Meta-analysis to identify emerging biomarkers of pancreatic adenocarcinoma pathogenesis

Authors*: Kamal Khorfan, Jihad Aljabban, Laraib Safeer, Hisham Aljabban, Maryam Panahiazar, Anne M. Noonan, Dexter Hadley

Abstract #: e16239 Abstract link: http://abstracts.asco.org/214/AbstView_214_226285.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e16239)

______

Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden

Authors*: Eric Jay Small, Fred Saad, Ying Zheng, Feng Pan, Maneesha Mehra, Joe Lawson, Boris A. Hadaschik, Hiroji Uemura, Ji Youl Lee, Paul N. Mainwaring, Matthew Raymond Smith

Abstract #: e17010 Abstract link: http://abstracts.asco.org/214/AbstView_214_218517.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e17010)

Small Research Interests: Dr. Eric Small’s current research program is based in the hypothesis that resistance to hormonal therapy for prostate cancer occurs when cancer cells exploit common cellular processes ultimately to evade the therapies, allowing disease progression. By identifying such “adaptive” mechanisms and inhibiting them, it is expected that treatment resistance may be delayed or prevented, profoundly improving the care of men affected by this fatal disease. http://cancer.ucsf.edu/people/profiles/small_eric.3671

______

59 *UCSF authors in bold National Comprehensive Cancer Network (NCCN) infusion efficiency workgroup study: Optimizing patient flow in infusion centers

Authors*: Jessica Sugalski, Daniel Mulkerin, Rebecca Caires, Penny J. Moore, Rosanna Fiorarancio Fahy, Jeanine N. Gordon, Connie Z. Augustyniak, Gina M. Szymanski, MiKaela M. Olsen, Diedra K. Frantz, Marisa A. Quinn, Sharol K. Kidd, Diana M. Cartwright, Lisa G. Kimbro, Robert W. Carlson, F. Marc Stewart

Abstract #: e18502 Abstract link: http://abstracts.asco.org/214/AbstView_214_217291.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e18502)

______

Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML)

Authors*: Sara Nunnery, Dorothy Wang, Marisela Tan, Richard Fong, Mimi Ming Lo, Rebecca L. Olin

Abstract #: e19009 Abstract link: http://abstracts.asco.org/214/AbstView_214_228757.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e19009)

Olin Research Interests: Dr. Rebecca Olin specializes in adult bone marrow transplantation (BMT) and the treatment of leukemia, lymphoma, myelodysplasia and myeloproliferative disorders, and multiple myeloma. In her research, she is particularly interested in the process of decision making in cancer treatment and the impact of cancer treatment on patient quality of life. She also studies how best to treat blood cancers in older patients. http://cancer.ucsf.edu/people/profiles/olin_rebecca.3372

______

60 *UCSF authors in bold IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCÎ¹ inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC)

Authors*: Masaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, Ilaria Attili, Laura Bonanno, Matteo Fassan, Jordi Berenguer, Jillian Bracht, Nuno Monteiro Gil, Morihito Okada, Andres Felipe Cardona Zorrilla, Niki Karachaliou, David Jablons, Peng Cao, Rafael Rosell

Abstract #: e24001 Abstract link: http://abstracts.asco.org/214/AbstView_214_211651.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e24001)

______

AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC

Authors*: Niki Karachaliou, Imane Chaib, Andres Felipe Cardona Zorrilla, Jordi Berenguer, Jillian Bracht, Jie Yang, Xueting Cai, Zhigang Wang, Ana Drozdowskyj, Ilaria Attili, July Katherine Rodríguez, Luis Leonardo Rojas Puentes, Santiago Viteri Ramirez, Sai-Hong Ignatius Ou, Tony Mok, Trever Grant Bivona, Mayumi Ono, Jingrong Jean Cui, Peng Cao, Rafael Rosell

Abstract #: e24003 Abstract link: http://abstracts.asco.org/214/AbstView_214_212795.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e24003)

Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for novel clinical trials we are launching to improve patient survival. http://www.bivonalab.net/

______

61 *UCSF authors in bold Methylomes variation to predict exemestane resistance in advanced breast cancer

Authors*: Xiao-Ran Liu, Ru-Yan Zhang, Hao Gong, Hope S. Rugo, Jian Tie, Lingbo Chen, Yuan Fu, Jianwei Che, Bin Shao, Feng-Ling Wan, Wei-yao Kong, Guo-hong Song, Han-fang Jiang, Guo-bing Xu, Huiping Li

Abstract #: e24029 Abstract link: http://abstracts.asco.org/214/AbstView_214_213355.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e24029)

______

Prospective comparison of invasive circulating tumor cells (iCTCs) vs PSA and mpfs in prostate cancer (PC) treated with SM-88

Authors*: Wen-Tien Chen, Terence W. Friedlander, Huang Dong, Qiang Zhao, Giuseppe Del Priore

Abstract #: e24072 Abstract link: http://abstracts.asco.org/214/AbstView_214_223757.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e24072)

Friedlander Research Interests: I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology of these malignancies and in developing novel therapeutic ways to treat disease. I have a research focus in developing novel immunotherapeutic approaches, particularly in bladder cancer, as well as in developing novel biomarkers, such as circulating tumor cells, to help understand how to better select patients for therapy. As a clinical academic oncologist I serve as principal investigator or co-investigator on a number of clinical trials in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work. http://cancer.ucsf.edu/people/profiles/friedlander_terence.4963

______

62 *UCSF authors in bold Sphingosine-1-phosphate to regulate cancer apoptosis by modulating cathelicidin production

Authors*: Shivtaj Mann, Kyungho Park

Abstract #: e24202 Abstract link: http://abstracts.asco.org/214/AbstView_214_210937.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e24202)

______

Intentions to pursue future cancer screening among older adults with limited life expectancy: Results from a US nationally-representative sample

Authors*: Ashwin A. Kotwal, Louise Christie Walter, Sei Lee, William Dale

Abstract #: e13546 Abstract link: http://abstracts.asco.org/214/AbstView_214_226461.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e13546)

Lee Research Interests: Sei Lee is an Associate Professor in the Division of Geriatrics and Senior Scholar for the San Francisco VA Quality Scholars fellowship. His research focuses on improving the targeting of preventive interventions in older adults to maximize benefits and minimize harms. Dr. Lee current project focuses on cancer screening and was conducted with colleagues Dr. Ashwin Kotwal (Geriatrics and Palliative Care, UCSF), Dr. Louise Walter (Geriatrics, UCSF) and Dr. William Dale (Geriatrics and Palliative Care, City of Hope). https://geriatrics.ucsf.edu/about/faculty_profiles.html?key=4a8e5672554202a06d7e7aa6201161d8&name=LEE%2CSEI+J

______

63 *UCSF authors in bold Determinants of guideline-based treatment in patients with cT1 bladder cancer

Authors*: Ashwin Balakrishnan, Samuel L. Washington, Maxwell V. Meng, Sima P. Porten

Abstract #: e16518 Abstract link: http://abstracts.asco.org/214/AbstView_214_228581.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e16518)

______

Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry

Authors*: Celestia S. Higano, Andrew J. Armstrong, A. Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, David F. Penson, Neal D. Shore, Jeffrey L. Vacirca, Raoul S Concepcion, Ronald F Tutrone, Luke T. Nordquist, David I. Quinn, Vahan Kassabian, Mark C. Scholz, Robert C. Tyler, Nancy N. Chang, Bruce Brown, Matthew R. Cooperberg

Abstract #: e17018 Abstract link: http://abstracts.asco.org/214/AbstView_214_222973.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e17018)

Cooperberg Research Interests: Dr. Cooperberg’s clinical interests are early detection, diagnosis & management of GU malignancies. His research focus is prostate cancer, particularly in 1) health services research, documenting trends & regional variation in the use of diagnostic, imaging & therapeutic interventions; 2) risk assessment, developing & validating prognostic tools including novel biomarker and imaging tests; 3) comparative effectiveness research, examining the relative benefits of treatments in terms of cancer control, QoL, & cost; and 4) decision support and survivorship, helping men make better-informed decisions about treatment options & management. He has led efforts by the American Urological Association to develop and launch the national AUA Quality registry & continues to serve as senior physician advisor to the project. http://cancer.ucsf.edu/people/profiles/cooperberg_matthew

______

64 *UCSF authors in bold c15-149: A phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC)—A prostate cancer clinical trials consortium study

Authors*: Catriona Lewis, David C. Smith, Benedito A. Carneiro, Charles J. Ryan, Tammy J. Rodvelt, Mina Lee, Terence W. Friedlander, Amy M. Lin, Won Kim, Brigid Miralda, Gregory Campbell, Rahul Raj Aggarwal Abstract #: e17028 Abstract link: http://abstracts.asco.org/214/AbstView_214_225491.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e17028)

Aggarwal Research Interests: I am an Assistant Clinical Professor of Medicine in the Department of Medicine, Hematology/Oncology within the Genitourinary Oncology and Developmental Therapeutics programs. My research program is focused upon developing novel therapeutic and imaging strategies for patients with advanced prostate cancer. I serve as Co-Investigator in the ongoing Prostate Cancer Foundation/SU2C-funded West Coast Dream Team prostate cancer consortium, focused on clinically and genomically characterizing metastatic tumor biopsies, including those with oligometastatic disease. Thus far approximately 10% of our patients have oligometastatic disease, and we anticipate a larger percentage as begin to biopsy patients earlier in their disease course. The infrastructure of this program will provide the mechanism to genomically characterize oligometastatic disease and compare with patients with more extensive disease, to understand if there are intrinsic biologic differences between these disease subtypes. http://cancer.ucsf.edu/people/profiles/aggarwal_rahul.7339

______

Nurse practitioner and physician assistant oncology workforce for older adults

Authors*: Lorinda Adaire Coombs, Caroline Stephens, Tatjana Kolevska, Wendy Max

Abstract #: e18514 Abstract link: http://abstracts.asco.org/214/AbstView_214_221995.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e18514)

______

65 *UCSF authors in bold Differences in chemotherapy-induced neuropathy (CIN) among younger and older cancer survivors

Authors*: Melisa L. Wong, Bruce A. Cooper, Judy Mastick, Melissa Mazor, Christine Miaskowski

Abstract #: e22022 Abstract link: http://abstracts.asco.org/214/AbstView_214_215383.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e22022)

Miaskowski Research Interests: I am an internationally recognized expert in pain and symptom management research. A portion of my program of research focuses on the identification of phenotypic and genotypic characteristics that place patients at highest risk for the development of the most deleterious symptoms that occur as a result of cancer and its treatment. More recently, my work is focused on an evaluation of differences in the co-occurrence of multiple symptoms in younger versus older oncology patients. http://cancer.ucsf.edu/people/profiles/miaskowski_christine.3393

______

Effect of risk communication on anxiety, breast cancer worry and risk perception in women at high risk of breast cancer

Authors*: Zhuoer Xie, Neil Wenger, Liliana Johansen, David Elashoff, Jacqueline Trent, Kristina Lee, Celia Kaplan, Lisa Madlensky, Tracy M. Layton, Antonia Petruse, Arash Naeim

Abstract #: e22129 Abstract #: http://abstracts.asco.org/214/AbstView_214_217963.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e22129)

______

66 *UCSF authors in bold Hyperpolarized C-13 pyuvate metabolic MR imaging of solid tumor liver metastases as a biomarker of PI3K/mTOR pathway activity

Authors*: Rahul Raj Aggarwal, Zihan Zhu, Michael Ohliger, Jeremy Gordon, Robert A. Bok, Jim Slater, John V. Kurhanewicz, Emily Boyd, Susan Calabrese, Christopher E. Sotto, Daniel B. Vigneron, Pamela N. Munster

Abstract #: e24168 Abstract #: http://abstracts.asco.org/214/AbstView_214_221551.html Presentation Date/Time: Location: Presentation Type: Citation: J Clin Oncol 36, 2018 (suppl; abstr e24168)

Munster Research Interests: Our lab is interested in developing novel strategies to overcome hormone therapy resistance in breast cancer. http://cancer.ucsf.edu/people/profiles/munster_pamela.3449

67 *UCSF authors in bold SUMMARY OF ABSTRACTS BY FACULTY MEMBER

Rahul Aggarwal, MD 5039 DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team TPS5090 A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19) e17028 c15-149: A phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC)—A prostate cancer clinical trials consortium study

Edwin Alvarez, MD TPS5600 GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator’s choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer

Charalambos “Babis” Andreadis, MD 7505 Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL

Sarah Arron, MD, PhD 9577 A multi-gene risk signature for improved identification of cutaneous squamous cell carcinoma (cSCC) patients with a high risk of recurrence

Chloe Atreya, MD, PhD 3514 KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer

Emily Bergsland, MD TPS4147 Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas

Trever Bivona, MD, PhD 9083 Concurrent genomic alterations in lung adenocarcinoma with a METexon 14 skipping mutation e24003 AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC

68 9541 9516 9511 9506 9503 Daud,Adil MD e17018 5041 Cooperberg,Matthew MD, MPH 2037 2002 Jennifer Clarke, MD, MPH TPS5092 Peter Carroll, MD, MPH 2061 2058 Butowski,Nicholas MD 541 520 Laura MD, Esserman, MBA metastatic melanoma immunotherapy, stageIIIb-IV treatment combination patients unresectable in with or ipilimumab and of HF10, for trial aphaseIImulticenter areplication-competent genetic and Efficacy analysis HSV-1 oncolytic KEYNOTE-001 in (pembro) outcomes treated patients pembrolizumab in (pts) advanced with survival with melanoma 5-year study phase2results Updated ofECHO-204 Epacadostat for the advanced nivolumab plus melanoma: therapy first-line as receiving pembrolizumab carcinoma advanced cell regression (aMCC) tumor overallDurable patients and (OS)in with Merkel survival KEYNOTE-006 in (ipi)-naive advanced melanoma ipilimumab with (pembro) patients after in (pts) outcomes and after of 2-years pembrolizumab cessation survival 4-year for metastatic castration-resistant prostate registry cancer results from (mCRPC): PROCEED the Cerebrovascular event outcome overall (CVE) patients and (OS)in (pts) treated survival sipuleucel-T with (sip-T) patients in (pts) metastatic with castration-resistantquartiles prostate registry cancer PROCEED (mCRPC): Sipuleucel-T (sip-T) prostate-specific (BL) outcomes overall clinical by (OS)and (PSA) baseline antigen survival pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma neuro-oncology in scale aprospective in (NANO) Neurologic assessment of antibody, anti-PD1 phaseIItrial including glioma Phase 1 study of AG-881, tumors, advanced solid IDH1/IDH2, of patients mutant in with IDH-mutant inhibitor an of diagnostic accuracyExamination (OSPREY) A prospective study phase2/3multicenter of 18F-DCFPyL PET/CT prostate patients in with imaging cancer: Dianhydrogalactitol of aphase bevacizumab-refractory in analysis 1-2 trial Further GBM: longer-term survival of SL-701 2 trial Phase relapsed/refractory with in response Correlation of (GBM): immune (r/r)glioblastoma Retrospective ofSTO-3 the analysis trial Long-term from benefit tamoxifen therapy Luminal for patientsA with Bbreast cancer: Luminal and cancerResidual burden (RCB) prognostic as I-SPY the in 2 TRIAL 69

SUMMARY OF ABSTRACTS BY FACULTY 9030 9026 Gubens,Matthew MD e24072 4532 Terence Friedlander, MD 5072 5019 TPS4586 4521 Lawrence Fong, MD 5045 5012 535 Feng,Felix MD 5001 Hope,Thomas MD e16239 e15601 Hadley,Dexter MD, PhD 10542 Gustafson,Clay MD, PhD Results fromResults KEYNOTE-001 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: therapy for NSCLC advancedfirst-line nonsquamous as 24-month overall from G:Pemetrexed-carboplatin pembrolizumab survival KEYNOTE-021 cohort plus treated SM-88 with Prospective of invasive comparison circulating (iCTCs) cells tumor vsPSA prostate in mpfs and cancer (PC) orabove)(second-line phase in 1/2 dose-escalation study 1108 outcomes carcinomaPatient-reported urothelial treated (PROs) durvalumab (UC) patients in with with treatment for prostate cancer receptor B-cell the in Association of changes overall after repertoire with (BCR) sipuleucel-T survival (sip-T) cancer (mCRPC) KEYNOTE-046: (pembro) metastatic in castration-resistantADXS-PSA pembrolizumab plus prostate chemotherapy: KEYNOTE-698/ECHO-303 platinum-containing carcinoma after (UC) of first-line failure (pembro)epacadostatPembrolizumab plus orplacebo for locally advanced ormetastatic urothelial advanced from follow-up cancer urothelial 2-year phase3KEYNOTE-045trial the (UC): (pembro)Pembrolizumab versus investigator’s choice (paclitaxel, docetaxel, recurrent, in orvinflunine) cancer (mCRPC): A phase 1b Prostate Cancer Clinical study Trials Consortium CC-115 plus c15-160: (ENZA) metastatic with castration-resistant men in Enzalutamide prostate mCRPC in benefit characterization genomic and Phenotypic of CTCs for prediction abiomarker as of therapyVeliparib systemic therapy Comprehensive breast transcriptomic cancer profiling to identify patients that maybespared adjuvant prospective trial Accuracy PET/CT of 68Ga-PSMA11 on recurrent prostate results from aphase2/3 cancer: Preliminary of pancreatic biomarkers emerging adenocarcinoma to pathogenesis identify Meta-analysis reveals drivers ofMeta-analysis colorectal multiple cancer pathogenesis tumors,CNS lymphomas and relapsed/refractory with young children adults and in of CUDC-907 tumors, solid trial Imulticenter Phase 70

SUMMARY OF ABSTRACTS BY FACULTY Robin Kate Kelley,Robin MD e22129 Celia Kaplan, PhD 7573 Lawrence Kaplan, MD 6010 Richard Jordan, DDS, PhD 8515 Jahan, MD Thierry e24001 David Jablons, MD 511 Chiung-Yu Huang, PhD TPS4144 4090 4088 4087 4083 4019 breast cancer communicationEffect onanxiety, of risk perception of risk at risk and women in high breast cancer worry AMC075: R-EPOCH aggressiveA in of vorinostatwith HIV-related randomized phase IItrial NHL carcinoma local-regionally cell RTOG (HR) advanced (HNSCC): necksquamous and head high-risk 3504 Safety evaluation (Nivo) concomitant cetuximab-radiotherapy of nivolumab and with for (IR) intermediate inactivation BAP1 with (MM) or refractory mesothelioma (R/R)malignant relapsed with monotherapy tazemetostat as adults in inhibitor 2,Phase study multicenter ofEZH2 the cancer lung cell (NSCLC) non-small cell squamous and mutant mutant, KRAS for EGFR IPA-3 (PAK1 orOTSSP167 (PKCÎ¹inhibitor), option inhibitor) atherapeutic auranofin plus inhibitor) (MELK breast HER2-positive cancer operable primary patients with in trastuzumab and pathological complete with to tomography (pCR) pertuzumab response emission (PET) correlation uptake the of standardized onpositron (SUV) value assessing trial IIclinical Phase TBCRC026: patients with unresectable carcinomapatients with hepatocellular (HCC):HIMALAYA study treatment in first-line (T)as A tremelimumab (D)and randomized, phase3study multicenter of durvalumab advanced carcinomawith hepatocellular (HCC) (C)versus placebo of patients cabozantinib (P)in (pts) trial phase 3CELESTIAL the onagein Outcomes based (C)versus placebo of advanced cabozantinib (P)in carcinoma hepatocellular (HCC) trial CELESTIAL Outcomes patients in (pts) hadreceived who systemic sorafenib therapy prior phase3 only the the in (S)as analyses cancers outcomes biomarker and Clinical (ABC): advancedin biliary macrophage granulocyte plus factor (PEM) colony stimulating of pembrolizumab (GM-CSF) 2trial Phase carcinomahepatocellular (HCC) sorafenib (SORA)patients orwithout in (pts) advanced with with Phase (ENZA) 1B study of enzalutamide received sorafenib: from prior trial Results randomized the phase 3CELESTIAL (C)versus placebo patients (P)in (pts)Cabozantinib advanced carcinoma have with hepatocellular (HCC)who 71

SUMMARY OF ABSTRACTS BY FACULTY TPS8060 TPS8055 8014 MD Martin, Thomas 7000 Mannis,Gabriel MD 10500 10518 Loh,Mignon MD e13546 Lee,Sei MD 3577 W. Korn, Michael MD e16207 1591 Andrew Ko, MD e22022 Miaskowski,Christine RN, PhD, FAAN 10558 10522 Matthay,Katherine MD with relapsed/refractorywith (RRMM) myeloma multiple patients (Kd)vsKdin dexamethasone and carfilzomib plus Isatuximab study design: III(IKEMA) Phase (NDMM) myeloma multiple patients diagnosed (pts) newly vs with transplant-ineligible VRd in (R), (d) (V), dexamethasone bortezomib and lenalidomide plus Isatuximab study design: III(IMROZ) Phase refractory relapsedand in (RRMM) myeloma +carfilzomib multiple I-bstudy ofPhase isatuximab of aphase Results 1 study (IVO;Ivosidenib AG-120) relapsed/refractory IDH1 mutant in acute (R/R myeloid leukemia AML): malignancy t-cell diagnosed newly in COG nelarabine A testing AALL0434: randomized trial consortium A from LEAP report the Matched targeted relapsed, therapy patients for with pediatric refractory leukemias: orhigh-risk US nationally-representative sample lifeexpectancy: limited from to futureIntentions pursue cancer with Results a adults older screening among cancer (CRC) (AYA) adolescents young in adults and tumors of left-right-sided and analyses Molecular colorectal with patient-level meta-analysis resectable (borderline) patients in with pancreatic FOLFIRINOX cancer:Neoadjuvant A systematic review and pancreatic in rate testing attrition and Referral patterns for cancer germline (PC)patients Differences cancer chemotherapy-induced older in neuropathy and younger among survivors (CIN) refractory neuroblastoma high-risk NANT 2012-01: Phase cyclophosphamide topotecan1 study and for ofcelecoxib with DFMOand relapsedor neuroblastoma (RR-NB) ch14.18A with phaseINANT study of refractory/recurrent lenalidomide patients isotretinoinin with and (RA) 72

SUMMARY OF ABSTRACTS BY FACULTY e24168 TPS2604 2578 2557 2554 9018 6031 1546 1044 106 Pamela Munster, MD 10504 10537 Sabine Mueller, MD, PhD 2006 Annette Molinaro, MA, PhD e19009 10030 Rebecca Olin, MD 10083 Dixit, MD Niharika of PI3K/mTOR pathway activity C-13Hyperpolarized pyuvate liver abiomarker of tumor as solid metastases imaging metabolic MR tumors solid A phase 1 study evaluating safety, the activity patients ofin with MM-310 preliminary and pharmacology relapsed/refractory tumors (R/R) solid patients in with durvalumab plus (BTK)A ibrutinib tyrosine kinase study inhibitor multicenter of Bruton’s the advancedin tumors solid Phase 1 study of ANDES-1537: DNA non-coding mitochondrial A against novel oligonucleotide antisense phase dose-finding The A patients in (pts)tumors: phase (nab-pac) solid with 1/2 study of +nab-paclitaxel relacorilant NSCLC in anti-PD-1 and durability and treated pegilodecakin with Responses Alliance A091101 (Carbo-Tax) carcinoma cell (HNSCC) necksquamous and head carboplatin-paclitaxel patients in with to (PARP) induction polymerase veliparib inhibitor addingpoly(ADP-ribose) A phaseI/IItrial cancerPopulation and pilot protocol testing health (PHACT) resistant breast cancer predictive after epigenetic inhibitors priming checkpoint ofto response immune (Tex) CD8+cells Exhausted to predict to response PD-1 therapy estrogen in receptor therapy (+)hormone advancedwith triple-negative breast cancer orrecurrent cancer ovarian from (ROC)—Results ROC cohort TOPACIO/Keynote-162 (NCT02657889): A patients in (pts) phase +pembrolizumab 1/2 study of niraparib A study phaseI/IIa Trametinib neurofibromatosis patients with pediatric type in 1 (NF-1)–associated neurofibroma: plexiform orneurofibromatosis tumors solid type progressive1 (NF1) neurofibromas plexiform (PN) relapsed dabrafenib adolescents children and in with with combination in Phase and alone of trametinib 1 trial for bevacizumab recurrent patients. plus (rGBM) orpembrolizumab glioblastoma IIstudy ofPhase pembrolizumab acute (R/R myeloid leukemia AML) cost-effectiveness and forEfficacy treatment cytarabine of high-dose relapsed/refractory of with clofarabine (AutoHCT)hematopoietic transplant cell Impact autologous functional undergoing of adults onoverall patient older reported in limitation survival self-efficacy for and breastPCPs forcolon and cancer caring knowledge survivors 73

SUMMARY OF ABSTRACTS BY FACULTY e24029 e13018 110 1002 TPS1113 TPS1111 TPS1107 TPS1106 1070\ 1069 1060 1059 1053 1040 1023 Rugo,Hope MD e16518 Porten,Sima MD, MPH 1553 Palefsky,Joel MD 10536 Amit Sabnis, MD Methylomes variation to variation Methylomes predict resistance exemestane advanced in breast cancer positive metastatic HER2 breast patientsPrognostic in with cancer copy gene number role HER2 of plasma Toxicity, efficacy, trial from phase 3Heritage the immunogenicity and monotherapy monotherapy after versus therapy: trastuzumab combination trastuzumab-dkst Biosimilar HR+, advanced with women HER2- breast cancer for pre/perimenopausal Abemaciclib correlative genomic and immunologic studies breast in cancer disease, compared alone to wall chest carboplatin carboplatin patients with with with A randomized phaseIIstudy of pembrolizumab, (programmed anti-PD an death) cell 1 antibody, combination in anthracycline, (ATC) capecitabine a taxane, and metastaticwith breast cancer previously have (BM) who metastases (MBC) brain treated an stable with ATTAIN: vs. (EP) 3study of pegol Phase etirinotecan treatment of physician’s patients choice in (pts) (TPC) advanced breast cancer (CDK4/6i)therapy (aBC)progressing 4/6inhibitor on/after kinase cyclin-dependent mutant, receptor-positive hormone factor growth epidermal (HR+), receptor human 2-negative (HER2–) forBYLieve: treatment fulvestrantorletrozole of with PIK3CA (FUL) (LET) (ALP) A phase IIstudy of alpelisib receptor HER2-, hormone with locally +(HR+) advanced ormetastatic breast cancer (MBC) Contessa: A multinational, multicenter, randomized, phase3registration patients in (Pts) study of tesetaxel (TALA) breast cancer treated talazoparib with (TNBC) receptor-positive BRCA1/2 hormone mutated (gBRCAmut) of germline Analysis negative triple and (HR+) BRCAmutation cancer agermline and (PARP) polymerase ribose inhibitor, to physician’s choice of therapy (PCT) advanced patients in with breast (TALA), relevant talazoparib outcomes oral clinically Efficacy an in poly EMBRACA: subgroupsADP comparing fromPooled randomized 3studies analysis phase2and (ABC): cancer receptor-positive factor growth epidermal receptor (HR+)/human 2-negative advanced (HER2–) breast Hematologic adverse events (PAL) palbociclib following dose reduction patients in (pts) hormone with abemaciclib plus pembrolizumab efficacy,Updated safety, HR+, status metastatic of &PD-L1 patients with breast HER2- cancer administered outcomes toxicity and for patients treated association abemaciclib ofThe early with estrogen receptor positive (+)metastatic (ER) breast cancer (B2151009) (MBC) with women in therapy endocrine and (ET) palbociclib with combination study in of Ib gedatolisib Phase ofA PALOMA2 jointanalysis PALOMA3 and Treatment effect of (PAL) palbociclib by subtype: prognostic therapy endocrine (ET) plus intrinsic and cancer cT1bladder treatment patients in with of guideline-based Determinants end-ofstudy analysis 10-year Long-term HPV of quadrivalent effectiveness vaccine immunogenicity young men: and in adults with recurrent with adults orrefractory tumors solid Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, children, in adolescents, young and 74

SUMMARY OF ABSTRACTS BY FACULTY Laura van ‘t Veer, PhD e18514 Wendy Max, PhD 7017 Catherine Smith, MD e17010 LBA5005 5034 5033 5032 5027 J.Eric Small, MD TPS7586 Shah,Nina MD 11008 VanKatherine Loon, MD, MPH 12103 12099 1506 Nurse practitionerNurse oncology physician and workforce assistant for adults older treatment (TKI) inhibitors FLT3-ITD–mutated relapsed/refractory (mu) (R/R) prior AML orwithout 1st-generation with FLT3 tyrosine kinase monotherapy patients in (pts) with of quizartinib Post phase2trials of two hoc exploratory analysis metastatic castration-resistant prostate burden cancer disease (mCRPC) nonmetastatic castration-resistantImpact high-risk in prostate of intervening cancer on (HRnmCRPC) prostate cancer (mCRPC) metastatic between CaucasianAfrican-American with castration-resistant and Overall (C)men survival (AA) fromcancer phase3SPARTAN the (nmCRPC): analysis An trial Predicting progression disease patients in (pts) nonmetastatic castration-resistant with prostate castration-resistant prostate from cancer Results phase3SPARTAN the (nmCRPC): trial patients in (pts) site of nonmetastatic and metastases with (TTM) to of metastasis time Relationship prostate cancer (nmCRPC) overall (MFS) nonmetastatic and (OS)in castration-resistantAssociation of survival metastasis-free survival patientsin (pts) metastatic with castration resistant prostate cancer (mCRPC) sipuleucel-T between Relationship (sip-T) cytolytic T lymphocyte (CTL) activity overall and (OS) survival conjugate,antibody drug advanced patients malignancies in with B-cell A phase 1 open-label, safety, pharmacokinetic, efficacy study of STRO-001, preliminary and anti-CD74 an global oncologyglobal of career development and academic for of emerging amodel field training the Implementation in I-SPYpatients the in 2trial Association of HER2+ activation in trebananib inhibitor levels to angiogenesis response of the with TIE2 patients HER2+ and HER2- both in substrates of to kinase predictAKT Phosphorylation I-SPY the MK2206in to2trial response the inhibitor AKT A apredictor breast as cancermodel risk cancer of rate interval characteristics tumor and 75

SUMMARY OF ABSTRACTS BY FACULTY — TPS9599 S.Sue Yom, MD, PhD 8034 Arun Wiita, MD, PhD TPS10576 TranKieuhoa Vo,MD, MAS e16107 4012 3570 Venook,Alan MD Treatment Strategies for Locoregionally of Recent Studies Cancer: Sense Making Advanced Nasopharyngeal stereotacticplus body radiation therapy carcinoma advanced cell in (Alliance merkel A091605) A randomized versus antibody phaseIIstudy alone anti-PD1 of antibody[MK-3475(Pembrolizumab)] anti-PD1 the treatment of multiple myeloma Pre-clinical development of TNB-383B, human T-cell afully antibodytargeting BCMA bispecific for engaging advanced with sarcoma youngchildren adults and for temozolomide(PAZIT) and irinotecan with combination in of pazopanib pharmacodynamics tolerated dose, maximum the safety,Phase to assess trial 1 multicenter pharmacokinetics, and treated sorafenib CALGB80802 with (S)in (Alliance) (C8) outcomes patients and in (pts) advanced (Plt) Platelet count carcinoma at with hepatocellular (HCC) baseline therapy cancer for esophageal modality outcomes fromSurvival CALGB 80803(Alliance): A ofscan-directed PET randomized phaseIItrial combined of CALGB modeling Causal drivers of network metastatic 80405(Alliance) to colorectal identify cancer (CRC) 76

SUMMARY OF ABSTRACTS BY FACULTY SUMMARY OF ABSTRACTS BY INDICATION

BREAST CANCERS

520 Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL Laura Esserman, MD, MBA

541 Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial Laura Esserman, MD, MBA

535 Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy Felix Feng, MD

511 TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer Chiung-Yu Huang, PhD e22129 Effect of risk communication on anxiety, breast cancer worry and risk perception in women at high risk of breast cancer Celia Kaplan, PhD

106 TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort Pamela Munster, MD

1044 Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint inhibitors after epigenetic priming Pamela Munster, MD

1023 Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3 Hope Rugo, MD

1040 Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009) Hope Rugo, MD

1053 The association of early toxicity and outcomes for patients treated with abemaciclib Hope Rugo, MD

TPS1111 TPS1107 TPS1106 1070 1069 1060 1059 e24029 e13018 110 1002 TPS1113

Hope Rugo,Hope MD receptor HER2-, hormone with patients locally (Pts) +(HR+) advanced ormetastatic breast cancer (MBC) Contessa: A multinational, multicenter, randomized, phase3registration in study of tesetaxel Hope Rugo,Hope MD HR+, advanced with women HER2- breast cancer for pre/perimenopausal Abemaciclib Rugo,Hope MD (TALA) breast cancer treated talazoparib with (TNBC) receptor-positive BRCA1/2 hormone mutated(gBRCAmut) of germline Analysis negative triple and (HR+) Rugo,Hope MD BRCAmutation breast cancer agermline and (PARP) polymerase ribose inhibitor,ADP to physician’s choice of therapy (PCT) advanced patients in with (TALA), relevant talazoparib outcomesoral clinically Efficacy an poly in EMBRACA: subgroups comparing Rugo,Hope MD fromcancer Pooled randomized 3 studies (ABC): analysis phase2and receptor-positive factor growth epidermal receptor (HR+)/human 2-negative advanced (HER2–) breast Hematologic adverse events (PAL) palbociclib following dose reduction patients in (pts) hormone with Rugo,Hope MD administered abemaciclib plus pembrolizumab efficacy,Updated safety, HR+, status metastatic of &PD-L1 patients with breast HER2- cancer Hope Rugo,Hope MD Rugo,Hope MD breast cancer Methylomes variation to variation Methylomes predict resistance exemestane advanced in breast cancer positive metastatic HER2 patientsPrognostic in with copy gene number role HER2 of plasma Hope Rugo,Hope MD anthracycline, (ATC) capecitabine ataxane, and metastatic breastwith cancer previously have (BM) who metastases (MBC) brain treated an stable with Rugo,Hope MD (CDK4/6i) therapy advanced(HER2–) breast cancer (aBC)progressing 4/6inhibitor on/after kinase cyclin-dependent PIK3CA mutant,receptor-positive hormone factor growth epidermal (HR+), receptor human 2-negative ATTAIN: vs. (EP) 3study of pegol Phase etirinotecan treatment of physician’s patients choicein (pts) (TPC) forBYLieve: treatment fulvestrant orletrozole of with (FUL) (LET) (ALP) A phaseIIstudy of alpelisib Hope Rugo,Hope MD Toxicity, efficacy, trial from phase3Heritage the immunogenicity and Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy monotherapy after versus therapy: trastuzumab combination trastuzumab-dkst Biosimilar Hope Rugo,Hope MD correlative genomic and disease, immunologic studies with breast in cancer compared alone to wall chest carboplatin carboplatin patients with with combination A randomized phaseIIstudy of pembrolizumab, (programmed anti-PD an death) cell 1 antibody, in 78

SUMMARY OF ABSTRACTS BY INDICATION

ENDOCRINE CANCERS ENDOCRINE TPS9599 9541 9516 9511 9506 9503 CUTANEOUS CANCERS e15601 3514 GASTROINTESTINAL TPS4147

Chloe Chloe Atreya, MD, PhD colorectal cancer KEYNOTE-164: (MSI-H) high advanced for Pembrolizumab patients with microsatellite instability Daud,Adil MD unresectable ormetastatic melanoma HSV-1 oncolytic immunotherapy, stageIIIb-IV treatment combination patients in with ipilimumab and of HF10, for trial aphaseIImulticenter areplication-competent genetic and Efficacy analysis Daud,Adil MD KEYNOTE-001 in (pembro) outcomes treated patients pembrolizumab in (pts) advanced with survival with melanoma 5-year Daud,Adil MD study phase2results Updated ofECHO-204 Epacadostat forthe advanced nivolumab plus melanoma: Daud,Adil MD therapy first-line as receiving pembrolizumab carcinoma advanced cell regression (aMCC) tumor overallDurable patients and (OS)in with Merkel survival Daud,Adil MD KEYNOTE-006 in (ipi)-naive advanced melanoma ipilimumab with (pembro) patients afterin (pts) outcomes and after of 2-years pembrolizumab cessation survival 4-year Dexter Hadley,Dexter MD, PhD Meta-analysis reveals drivers ofMeta-analysis colorectal multiple cancer pathogenesis Emily Bergsland, MD Emily Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas therapy previously in Pembrolizumab-based treated grade extrapulmonary high Sue S.Sue Yom, MD, PhD stereotacticantibody plus body radiation therapy carcinoma advanced cell in (Alliance merkel A091605) A randomized versus phaseIIstudy alone anti-PD1 of antibody [MK-3475(Pembrolizumab)] anti-PD1 (INCLUDES PANCREATIC CANCER) 79

SUMMARY OF ABSTRACTS BY INDICATION

3577 e16207 1591 TPS4144 4090 4088 4087 4083 4019 e16107 4012 3570

Alan Venook,Alan MD therapy cancer for esophageal modality combined outcomes fromSurvival CALGB 80803(Alliance): A of scan-directed PET randomized phaseIItrial Venook,Alan MD of CALGB modeling Causal drivers of network metastatic 80405(Alliance) to colorectal identify cancer (CRC) W. Korn, Michael MD colorectal cancer (CRC) (AYA) adolescents young adults in and tumors of left-right-sided and analyses Molecular with Andrew Ko, MD pancreatic in rate testing attrition and Referral patterns for cancer germline (PC) patients Kate Kelley,Robin MD patients (pts) advanced carcinoma with hepatocellular (HCC) (C)versus placebo of cabozantinib (P)in trial phase3CELESTIAL the onagein Outcomes based Kate Kelley,Robin MD (C)versus placebo of advanced cabozantinib (P)in carcinoma hepatocellular (HCC) trial CELESTIAL Outcomes patients in (pts) hadreceived who systemic sorafenib therapy prior phase3 the only the in (S)as Kate Kelley,Robin MD analyses cancers outcomes biomarker and Clinical (ABC): advanced biliary macrophage granulocyte plus factor (PEM) colony stimulating of pembrolizumab in (GM-CSF) 2trial Phase Kate Kelley,Robin MD carcinomahepatocellular (HCC) sorafenib (SORA)patients orwithout in (pts) advanced with with Phase (ENZA) 1B study of enzalutamide Kate Kelley,Robin MD havewho received sorafenib: from prior trial Results randomized the phase3CELESTIAL (C)versus placebo patients (P)in (pts)Cabozantinib advanced carcinoma with hepatocellular (HCC) Alan Venook,Alan MD treated sorafenib CALGB80802 with (S)in (Alliance)(C8) Andrew Ko, MD patient-leveland meta-analysis Platelet count at baseline (Plt) and outcomes patients and in (pts) advanced (Plt) Platelet count carcinoma at with hepatocellular (HCC) baseline resectable (borderline) patients in with pancreatic FOLFIRINOX cancer:Neoadjuvant A systematic review Robin Kate Kelley,Robin MD unresectable carcinomapatients with hepatocellular (HCC):HIMALAYA study A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in first-line (T)as A tremelimumab (D)and randomized, phase 3study multicenter of durvalumab 80

SUMMARY OF ABSTRACTS BY INDICATION

6031 6010 CANCERS NECK AND HEAND e16518 4532 TPS4586 4521 GENITOURINARY 10518 7573 7505 HEMATOLOGICAL MALIGNANCIES

Lawrence Kaplan, MD AMC075: R-EPOCH aggressiveA in of vorinostatwith HIV-related randomized phaseIItrial NHL “Babis” Andreadis,Charalambos MD (JCAR017)R/R aggressive in maraleucel NHL NHL outcomes 001, clinical in safety ofUpdated longterm lisocabtagene and pivotalTRANSCEND trial Richard Jordan, DDS, PhD carcinoma local-regionally cell RTOG (HR) advanced (HNSCC): necksquamous and head high-risk 3504 Safety evaluation (Nivo) concomitant cetuximab-radiotherapy of nivolumab and with for(IR) intermediate Terence Friedlander, MD orabove)(second-line phase in 1/2 dose-escalation study 1108 outcomes carcinomaPatient-reported urothelial treated (PROs) durvalumab (UC) patients in with with Lawrence Fong, MD advanced from follow-up cancer urothelial 2-year phase3KEYNOTE-045 trial the (UC): (pembro)Pembrolizumab versus investigator’s choice (paclitaxel, docetaxel, recurrent, in orvinflunine) Sima Porten,Sima MD, MPH Determinants of guideline-based treatment in patients with cT1 bladder cancer cT1bladder treatment patients in with of guideline-based Determinants Lawrence Fong, MD chemotherapy: KEYNOTE-698/ECHO-303 platinum-containing carcinoma after (UC) of first-line failure Pembrolizumab (pembro)epacadostatPembrolizumab plus orplacebo for locally advanced ormetastatic urothelial Pamela Munster, MD Alliance A091101 (Carbo-Tax) carcinoma cell (HNSCC) necksquamous and head carboplatin-paclitaxel patients in with to (PARP) induction polymerase veliparib inhibitor addingpoly(ADP-ribose) A phaseI/IItrial Mignon Loh, MD consortium A from LEAP report the Matched targeted relapsed, therapy patients forwith pediatric refractory leukemias: orhigh-risk (NON-PROSTATE) 81

SUMMARY OF ABSTRACTS BY INDICATION

7017 TPS7586 e19009 10030 TPS8060 TPS8055 8014 7000 10500 e24003 9083 LUNG CANCERS 8034

Trever Bivona, MD, PhD Concurrent adenocarcinomaa METexon alterations lung genomic in with 14 skipping mutation Arun Wiita, MD, PhD for myeloma treatment the of multiple Pre-clinical development of TNB-383B, human T-cell afully antibody targeting BCMA bispecific engaging Catherine Smith, MD treatment (TKI) inhibitors tyrosine kinase FLT3-ITD–mutated relapsed/refractory (mu) (R/R) prior AML orwithout 1st-generation with FLT3 monotherapy patients in (pts) with of quizartinib Post phase2trials of two hoc exploratory analysis MD Martin, Thomas refractory relapsedand in (RRMM) myeloma +carfilzomib multiple I-b study ofPhase isatuximab Gabriel Mannis, MD of aphase Results 1 study (IVO;Ivosidenib AG-120) relapsed/refractory IDH1 mutant in acute (R/R myeloid leukemia AML): Trever Bivona, MD, PhD Rebecca Olin, MD relapsed/refractory acute (R/R myeloid leukemia AML) AXL and CDCP1: and AXL A NSCLC roadmap mutant of resistance innate EGFR in cost-effectiveness and forEfficacy treatment cytarabine of high-dose of with clofarabine Nina Shah,Nina MD conjugate,antibody drug advanced patients malignancies in with B-cell MD Martin, Thomas relapsed/refractorywith (RRMM) myeloma multiple MD Martin, Thomas (NDMM) myeloma multiple patientsdiagnosed (pts) newly vs with transplant-ineligible VRd in A phase 1 open-label, safety, pharmacokinetic, efficacy study of STRO-001, preliminary and anti-CD74 an patients (Kd)vsKdin dexamethasone and carfilzomib plus Isatuximab study design: III (IKEMA) Phase (R), (V), (d) dexamethasone bortezomib and lenalidomide plus Isatuximab study design: III (IMROZ) Phase Rebecca Olin, MD (AutoHCT)hematopoietic transplant cell Loh,Mignon MD Impact autologous functional undergoing of adults onoverall patient older reported in limitation survival malignancy t-cell diagnosed newly in COG nelarabine A testing AALL0434: randomized trial 82

SUMMARY OF ABSTRACTS BY INDICATION

10522 2037 2061 2058 CANCERS NEUROLOGICAL 9018 e24001 9030 9026 10504 10537 2006 10558

Annette Molinaro, MA, PhD recurrent patients. (rGBM) glioblastoma for bevacizumab plus orpembrolizumab IIstudy ofPhase pembrolizumab Jennifer Clarke, MD, MPH antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma neuro-oncology in scale aprospective in (NANO) Neurologic assessment of anti-PD1 phase IItrial Butowski,Nicholas MD Dianhydrogalactitol of aphase bevacizumab-refractory in analysis 1-2 trial Further GBM: Butowski,Nicholas MD longer-term with response survival of SL-701 2trial Phase relapsed/refractory in Correlation of (GBM): immune (r/r)glioblastoma Pamela Munster, MD NSCLC in anti-PD-1 and durability and treated pegilodecakin with Responses Gubens,Matthew MD fromResults KEYNOTE-001 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Gubens,Matthew MD therapy for NSCLC advanced first-line as nonsquamous 24-month overall from G:Pemetrexed-carboplatin pembrolizumab survival KEYNOTE-021 cohort plus David Jablons, MD cancer lung cell (NSCLC) non-small cell squamous and mutant option mutant, KRAS for EGFR IPA-3 (PAK1 orOTSSP167 (PKCÎ¹inhibitor), inhibitor) atherapeutic auranofin plus inhibitor) (MELK Sabine Mueller, MD, PhD A study phaseI/IIa Sabine Mueller, MD, PhD orneurofibromatosis tumors relapsed solid type progressive1 (NF1) neurofibromas plexiform (PN) Matthay,Katherine MD or refractory neuroblastoma high-risk Matthay,Katherine MD refractory/recurrent neuroblastoma (RR-NB) Trametinib neurofibromatosis patients with pediatric type in 1 (NF-1)–associated neurofibroma: plexiform dabrafenibadolescents children and with in with combination in Phase and alone of trametinib 1 trial NANT 2012-01:Phase cyclophosphamide topotecan1 study and for ofcelecoxib with DFMOand relapsed ch14.18A with phaseINANT study of lenalidomide patients isotretinoin in with and (RA) 83

SUMMARY OF ABSTRACTS BY INDICATION

5045 e17018 5041 TPS5092 e17028 TPS5090 5039 CANCERS PROSTATE 5001 e24072 5072 5019

Thomas Hope,Thomas MD prospective trial Accuracy PET/CT of 68Ga-PSMA11 onrecurrent prostate results from aphase2/3 cancer: Preliminary Lawrence Fong, MD treatment for prostate cancer receptor B-cell the in Association of changes overall after repertoire with (BCR) sipuleucel-T survival (sip-T) Lawrence Fong, MD cancer (mCRPC) KEYNOTE-046: (pembro) metastatic in castration-resistantADXS-PSA pembrolizumab plus prostate Feng,Felix MD A phase (mCRPC): cancer 1b Prostate Cancer Clinical study Trials Consortium CC-115 plus c15-160: (ENZA) metastatic with castration-resistant men in Enzalutamide prostate Cooperberg,Matthew MD, MPH patients in (pts) metastatic with castration-resistantquartiles prostate registry cancer PROCEED (mCRPC): Sipuleucel-T (sip-T) prostate-specific (BL) outcomes overall clinical by (OS)and (PSA) baseline antigen survival MD Aggarwal, Rahul Data from the West Prostate Coast Cancer Dream Team of distinct subgroups of hallmarks metastaticas castration resistant prostate cancer (mCRPC): neuroendocrine prostate cell DNA treatment-emergent and small mutations repair cancer (t-SCNC) Matthew Cooperberg,Matthew MD, MPH for metastatic castration-resistant prostate registry cancer results from (mCRPC): PROCEED the Cerebrovascular event outcome overall (CVE) patients and (OS)in (pts) treated survival sipuleucel-T with (sip-T) Peter Carroll, MD, MPH of diagnosticaccuracyExamination (OSPREY) MD Aggarwal, Rahul (AFT-19) An Alliance Foundation trial A prospective study phase 2/3multicenter of 18F-DCFPyL PET/CT prostate patients in with imaging cancer: biochemically relapsedprostateA high-risk phase3studyin of androgen cancer: annihilation Terence Friedlander, MD treated SM-88 with Prospective of invasive comparison circulating (iCTCs) cells tumor vsPSA prostate in mpfs and cancer (PC) MD Aggarwal, Rahul study consortium prednisone metastatic in castration resistant prostate cancer (mCRPC)—A prostate cancer trials clinical c15-149: A plus phase docetaxel with combination in ribociclib 1b study oforal the CDK4/6inhibitor 84

SUMMARY OF ABSTRACTS BY INDICATION

TPS5600 SOLID TUMORS e17010 LBA5005 5034 5033 5032 5027 2578 2557 2554 2002

Edwin Alvarez,MD Edwin Eric J.Eric Small, MD prostate cancer (mCRPC) metastatic between CaucasianAfrican-American with castration-resistant and Overall (C)men survival (AA) Pamela Munster, MD relapsed/refractorywith tumors (R/R)solid patients in durvalumab plus (BTK)A ibrutinib tyrosine kinase study inhibitor multicenter ofBruton’s the Pamela Munster, MD advancedin tumors solid Phase 1 study of ANDES-1537: DNA non-codingmitochondrial A against novel oligonucleotide antisense Pamela Munster, MD phase dose-finding The A patients in (pts) tumors: phase (nab-pac) solid with 1/2 study of+nab-paclitaxel relacorilant Jennifer Clarke, MD, MPH tumors,solid including glioma Phase 1 study of AG-881, advanced IDH1/IDH2, of patients mutant in with IDH-mutant inhibitor an J.Eric Small, MD fromcancer phase3SPARTAN the (nmCRPC): analysis An trial Predicting progression disease patients in (pts) nonmetastatic castration-resistant with prostate J.Eric Small, MD castration-resistant prostate from cancer Results phase 3SPARTAN the (nmCRPC): trial patients in (pts) siteof nonmetastatic and metastases with (TTM) to of metastasis time Relationship J.Eric Small, MD prostate cancer (nmCRPC) overall (MFS) nonmetastatic and (OS)in castration-resistantAssociation of survival metastasis-free survival J.Eric Small, MD patientsin (pts) metastatic with castration resistant prostate cancer (mCRPC) sipuleucel-T between Relationship (sip-T) cytolytic T (CTL) lymphocyte activity overall and (OS) survival Eric J.Eric Small, MD metastatic castration-resistant prostate burden cancer disease (mCRPC) Impact of intervening in high-risk nonmetastatic castration-resistantImpact high-risk in prostate of intervening canceron (HRnmCRPC) anti-PD-1, versus investigator’s choice chemotherapy ≥ (IC) in GOG 3016/ENGOT-cx9: open-label,An multi-national, randomized, of cemiplimab, an phase3trial 85 2 line recurrent2 line ormetastaticcancer cervical

SUMMARY OF ABSTRACTS BY INDICATION

1553 10083 10542 SOLID/HEMATOLOGICAL TUMORS TPS10576 10536 TPS2604 e24168 e16239 5012 9577 BIOMARKERS

Sarah Sarah Arron, MD, PhD of recurrence risk ahigh patients with signature for improvedA risk multi-gene carcinoma cell (cSCC) identificationsquamous of cutaneous Palefsky,Joel MD end-of study analysis Long-term HPV of quadrivalent effectiveness vaccine immunogenicity young men: and in 10-year Pamela Munster, MD of PI3K/mTOR pathway activity Hadley,Dexter MD, PhD Hyperpolarized C-13Hyperpolarized pyuvate livera biomarker oftumor as solid metastases imaging metabolic MR of pancreatic biomarkers emerging adenocarcinoma to pathogenesis identify Meta-analysis Pamela Munster, MD tumors solid with A phase 1 study evaluating safety, the activity patients ofin MM-310 preliminary and pharmacology Felix Feng,Felix MD mCRPC in benefit characterization genomic and Phenotypic of CTCs for prediction abiomarker as of therapyVeliparib Dixit, MD Niharika self-efficacy for and breastPCPs forcolon and cancer caring knowledge survivors Kieuhoa TranKieuhoa Vo,MD, MAS advanced with sarcoma young adults and for children temozolomide(PAZIT) and irinotecan with combination in of pazopanib pharmacodynamics tolerated dose, maximum the safety,Phase to assess trial 1 multicenter pharmacokinetics, and Clay Gustafson,Clay MD, PhD tumors,CNS lymphomas and Amit Sabnis, MD recurrent with young adults and orrefractory tumors solid Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory with young children adults and in of CUDC-907 tumors, solid trial Imulticenter Phase Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, children, in adolescents, 86

SUMMARY OF ABSTRACTS BY INDICATION

e18514 1546 e22022 e13546 8515 OTHER 12103 12099 1506 — 11008

Pamela Munster, MD cancerPopulation and pilotprotocol testing health (PHACT) Jahan, MD Thierry inactivation BAP1 with (MM) refractory mesothelioma (R/R)malignant relapsed or with monotherapy tazemetostat as adults in inhibitor 2,Phase study multicenter ofEZH2 the Laura van ‘t Veer, PhD A apredictor breast as cancer model risk cancer of rate interval characteristics tumor and Wendy Max, PhD Miaskowski,Christine RN, PhD, FAAN Lee,Sei MD a US nationally-representative sample Nurse practitionerNurse oncology physician and workforce assistant for adults older Differences cancer chemotherapy-induced older in neuropathy and younger among survivors (CIN) life expectancy: limited from to futureIntentions pursue cancerwith Results adults older screeningamong Sue S.Sue Yom, MD, PhD Recent Studies Treatment Strategies for Locoregionally of Cancer: Sense Making Advanced Nasopharyngeal Katherine VanKatherine Loon, MD, MPH oncologyglobal Laura van ‘t Veer, PhD I-SPYpatients the in 2trial Laura van ‘t Veer, PhD patients HER2+ and HER2- both in trial Implementation of a model for training and career development in the emerging academic field of career development and academic offor emerging amodel field training the Implementation in Association of HER2+ activation in trebananib inhibitor levels to angiogenesis response of the with TIE2 substrates of to kinase predictAKT Phosphorylation I-SPY the MK2206in to2 response the inhibitor AKT 87

SUMMARY OF ABSTRACTS BY INDICATION